

Figure 2: Nucleotide sequence of TbF1S

Sheet 2 of 4

TTCCCTGGCCTTTGCTGGCTTTGCTCACATGTTCTTCCGTGATTACCGCTGATTCTGTGCGT  
 AACCGTATTACCGCCTTGAGTGAGCTGATACCGCTCGCCGAGCCGAAACGACCGAGCCAGCGAG  
 TCACTGAGCGAGGAAGCGGAAGAGGCCCTGATGCGGTATTTCTCCTAACCGCATCTGTGCGGTATT  
 TCAACCGCATATACTGACTCTCACTGACATCTGCTCTGATGCCCATAGTTAAGCCAGTATA  
 CACTCCGCTATCGCTACGTGACTGGTCATGGCTGCCGCCCCACACCCGCCAACACCCGCTGACGC  
 GCGCTGACGGGCTTGTCTGCTGCCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGAGCTG  
 CATGTGTGAGGTTTCACCGTCATCACCGAAACGCCGAGGCGCTGCGGTAAAGCTCATCAGC  
 CTGGTGGTGAAGCGATTACAGATGTCGCTGCTTCATCCGCTCCAGCTGTTGAGTTCTCCAG  
 AACCGTTAATGTCGCTTCTGATTAACGGGCCATGTTAACGGCGGTTTTTCTGTTGTCAC  
 TGATGCCCTCCGGTAAACGGGAGTTCTGTTGATGGGTAATGNTACCGATGAAACGAGAGAGGAT  
 GCTCACGNTRACGGGTTACTGATGATGACATGCCGGTTACTGGRAACCTTGTGAGGCTAACAACT  
 GCGGTTATGGATGCCGCCGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGGGCTTGGTTAAATAC  
 AGATGTAAGCTGTTCCACAGGTAGCCAGCAGGATCTGGATGCAAGATCCCGAACATAATGGTGC  
 GGGCGCTGACTTCGGGTTCCAGACTTTACGAAACACGGAAACCGGAAGACCAATTCAATGTTG  
 TCAGGTGGCAGACGTTTGGCAGCAGGAGTCGCTTCACGTTGGCTGGGTATGGGTGATTCACTG  
 CTAACCASTAAGCGAACCCCGGAGGCTAGCCAGGATCTGGATGCCAACAGGAGCACCGATCATGCCAC  
 CGTGGGCGGGCATGCCGGGATTAATGGGCTGCTCTGGGAAACGTTGGTGGCGGGACCGT  
 GACGAAAGCTTGGCAGGGCTGCAAGATTCCGAATACCGCAAAGGACAAAGCGATCATGGTGGC  
 GCTCCAGGAAACGGGTCTGCCCGAAAATGACCCAGAGGGCTGCCGGCACCTGTCCTACGAGTTG  
 CAGGATAAAGAGACAGTCTAAGTGGCGGAGGATAGTCATGCCCGGCGAACGGGAAGGAGCT  
 GACTGGGTGAAAGCTCTCAAGGTCATCGGTGAGATCCCGCTTAATGAGTGAGCTAACCTAC  
 ATTAAATGGCTTGGGCTCAGTGGGCTTTCCAGTGGGAAACCTGTCGCTGCCAGCTGCTTAATG  
 AATGGGCAACGCCGGGGGAGGGCTTGGGTATGGGCGCCAGGGTGTGTTCTTCAACCA  
 GTGAGACGGGAAACGCTGATTGGCCCTTCACGGCTGGCCCTGAGAGACTGCAAGAACGGCTCC  
 CGCTGGTTGGCCCAGCAGGGAAAATCTGTTGATGGTGGTTAACGGGGGATAAACATGAGC  
 TGTCTTGGTATGGTGTATCCCACTACCGAGATATCCGACCAACGGCCAGGGGACTGGTAA  
 TGGGCGGATTGGCCCGAGCCGCTCTGAGGCTGGTGGGCAACCGCATGGCAAGGGACTGGCT  
 CATTAGCATTCGATGGTTGTTGAAACCGGACATGGCACTCCAGTGGCTTCCCGTTGGCT  
 TGGCTGAATTGGATTGGGAGTGAGATATTATGCCAGCCAGGCAAGGCGGAGACAG  
 AACCTTAATGGGCCCGCTAACGCCGATTTGCTGGTGGCAACGCAATGGCAACGGGACTGGTAA  
 GTGCGCTACCGTCTTCATGGAGAAAATAATACTGTTGATGGGTGCTGGTCAGAGACATCAAGAA  
 ATAACGGCCGAACATTAGTGGCAAGGAGCTTCCACAGCAATGGCATCTGGCATCCAGGGAGATAGT  
 TAATGATCAGGCCACTGACGGCTTGGCGQAGAAGATTGTCACGGCCGGCTTACAGGCTTGGAGCC  
 CGCTGGTTCTACCATCGACACCACCGCTGGCACCCAGTTGATGGGGGGAGATTAAATGCCCG  
 CGACAATTGGGACGGCGGTGGCAGGGCCAGACTGGAGGTGGCAACGCCAATCGCAACGGCTT  
 TGGCCCGCAGTTGTTGGCAGGGCTTGGGATGTAATTCAAGCTGGCCATCGCCGCTTCCACTT  
 TTTCCCGCTTTGGCAAGAAAAGTGGCTGGCTGGTACCCACGGGGAAACCGCTGATAAGAGA  
 CACCGGGCATACTCTGCGACATCGTATAACGGTACTCGTTTACCATTCACCCACCCCTGAAATTGACTCT  
 CTTCCGGGGCTATCATGCCATACCGGAAGGGTTTGGCCATTGCGATGGTGTGGTGGGAGATCTGGA  
 CGCTCTCCCTTATGGGACTCTGCAATTAGGAGGCAAGGCCAGTACTGAGTTGAGGGGGTGGAGCC  
 GCGGCCGCAAGGAATGGTGCATGCCAGGGAGATGGGCGCCAAACAGTCCCCCGGCCACGGGGCCCTGCC  
 ACCATACCCACGCCGAACAGGCTCATGAGGGGGAAAGTGGGAGGGGAGATCTTCCCCATGGCTG  
 ATGTCGGGAGATAAGGCCGAGGCCACCGCATGGGCGGCGGTGATGCCGGGCCACGATGGGTGG

Figure 2: Nucleotide sequence of TbFl5  
Sheet 3 of 4

Figure 2: Nucleotide sequence of TbF15  
Sheet 4 of 4

CGGGCCCCCTGCCGCTGGTACATTGCCGGCTTAGGCCAGCGAAGGGCCGGGGGGCGCGCGCT  
GGCGCGCGGTGCCATGGGAATGCCGATGGGTGCCCGCATCAGGGACAAGGGGCCCGCAAGTCCAA  
GGGTTCTCAGCAGGAAGACGAGCCGCTCTACACCGAGGGATCGGGCATGGACCCAGGGCGGTCAATTGG  
TAACCGTCCGCAGGACAGTAAAGACTCGAAGTGAAATTCTGCAGATAATCCCATCACACTCGCGC  
CGCTCGAGCACCACCCACCCACCACTGAGATCCGGCTCTAACAAAGCCGAAAGGAAGCTGAGT  
TGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCTCTAAACCGGTCTTGAGGG  
GTTTTTGGTGAAGGAGGAAGTATAATCCGGAT

Figure 3: Amino Acid Sequence of TbFl4

MQHHHHHHHTDRVSVGNLRIARVLYDFVNNEALPGTDIDPDSFWAGVDKVADLTPQNQALLNARDE  
LQAQIDKWHRRRVIEPIEDMDAYRQPLTEIGYLLPEPDQPTITSGVDAEITTATGQLVVPVLNAR  
FALNAANARWGSILYDALYGTQVIPTOGAEKGPTYNKVRGDKVIAYARKFLDDOSVPLSSGSFGDAT  
GFTVQDGQLVVALPDKSTGLANPGQFAGYTGAAKESPTSVLLINGLHISILIDPESQVGTTDAGV  
KEVILESAITTIMDFEDSVAAVDAADKVLGYENWLGLNKGDIAAAVDKDGTAFLRVLRNRNYTAP  
GGCQPTLPGCRSLMFVRNVGHLMTNDIAVDTDGSEVFEGIMDALFTOLIAIHGLKASDVNGPLINSR  
TGSIYIVVKPKMHGPAEVAFTCELFSRVEDVLGLPQNTMKIGIMDEERRTTVNLKACIKAAAADRVVF  
INTGFLDRTGDEIHTSMEAGPMVRKGTMKSQFWILAYEDHNVDAGLAAGPSGRAQVGKGMWTMTEL  
MAADMVETKIAQPRAGASTAVPSPTAATLHALHYHQVDAVAVQQGLAGKRRATIEQLLTIPIAKEL  
ANAPDEIREEVDDNNCQSILGYVVRNWQGVGCSKVPDIHDVALMEDRATLRISSQLANWLHGVI  
TSADVRASSLERNAPLVDQRQAGDVAYRPMAFPNFDDGIAFLAAQELILSGAACQQPNGYTEPILNRRRR  
EFKARAAEKPAPSDRAGDOAARVOKYGGSSVADAERIRRVAAERIVATKKQGNDVVVVVSAMGDTTD  
DLDDLAQQVCPAPPRELDMLLTAGERISNALVAMATESLGAHARSFTGSQAGVTTTGTHGNAKII  
DVTGCRLOTALEEGRVVVLVAGFOGVSQDTKDVTTLGRGGSDTTAVAMAALGADVCEIYTDVDGIF  
SADPRIVRNARKLDTVTFEEMLEMAACCAXVLMILRCVEYARRHNIPVHVRSSYSDRPGTVVVGSIK  
DVPMDPILTGVAHDRSEAKVTIVGLFDIPGYAAKVFRAVARRRQHRRGAAERLQGRGRQDRHNL  
HLLPQTSGRPPWKNWTRSETRSASTQLLYDDHIGKVSLIGAGMRSHPGVTATPCEALAAVGVNIEL  
ISTSEDQRSRCCAATPNWTRPWSRCMRSQSAATRPRCTRGRDGRWACQ..

Figure 4: Amino Acid Sequence of TbF15

MGHMMNNNVIDIITGTSPSWEQAAACAVQRARDSVDDIRVARVIEQUMAVDSAGKITYRIKLEVSP  
KMRRPAQPRCGSKPPSGSPETGAGACTVATTFASSPVTLAETGSTLLYPLPNLWCPAFHERYPNVTI  
TQQGTGSQAGIAQARAGTVWIGASDAYLSECCDMAAHKCLMNIALAISQQVNINLPGVSENLKLNG  
KVLAAMYQGTIKTWDDPQIAALNPQVNLPGTAVVPLHRSRGSGDTFLFTQOYLSKQDPEGWGKSPGF  
CTTVDFPAVPGALGENGNQGMVTGCAETPGCVAYIGIISPLDQASQRGLGEAQLGNSGNFLLPDAQ  
SIQAAAAGPASKTPANQAIISMIDGPAPDGYPITNEYAIVNNRQDAATMQTLQAFLHWAITDGNK  
ASPLDQVHFQQLPPAVVKLSDALIATISSAEMKTDAAATLAQEAGNFERISGDLKTQIDQVESTAGS  
LQGQWRGAAGTAAQAAVVRQEAANKQKQELDQEISTMIRQAGVQYSRADEEQQQALGSQMGPTQSQ  
TVTVVDQQEILNRANEVEAPMADPFTDVEITPCELTAAKNAACQQLVLSDADMREYLAAGAKERQRLA  
TSLRNAAKAYGEVDEEAATALDNDGEHTVQAESAGAVGGDSASLTDTPRVATAGEPNFMDLKEAA  
RKLETGDQGASLANFADGWNTFNLTQGDVKFRGFDNWEGDAATACEASLDQQRQWILHMAXLSA  
AMAKQAOQYVAQLHVWARREHPTYEDIVGLERLYAENPSARDQILPVYAEYQQRSEKVLTEYNKAA  
LEFPVNPKPPPAAIKIDPPPPPQEQXGLIPGFLMPPSDGSGVTPGTGMPAAPMVPPPTGSPGGGLPADT  
AAQLTSAGREAAALSGDVAVKAAASLGCGGCCQVPSAPLCSAIGGAESVRPAGAGDIAGLCQGRAGG  
GAALGGCGNCMPMGAANQGQCGAKSKGSQQEDEALYTEDRAWTEAVIGNRRRQDSKESK.

Figure 5

	Status	TbF15	TbF6
5004	TB	0.925	0.347
7004	TB	0.928	0.184
9004	TB	0.901	0.187
11004	TB	0.875	0.199
15004	TB	0.914	0.099
17004	TB	0.902	0.086
18004	TB	0.417	0.418
21004	TB	0.182	0.183
23004	TB	0.419	0.301
26004	TB	0.289	0.392
27004	TB	0.244	0.207
28004	TB	0.205	0.204
30004	TB	0.154	0.108
32004	TB	0.237	0.077
33004	TB	0.156	0.118
34004	TB	0.165	0.143
36004	TB	0.146	0.185
37004	TB	0.146	0.189
39004	TB	0.101	0.187
41004	TB	0.111	0.651
43004	TB	0.335	0.433
44004	TB	0.731	0.161
53004	TB	0.109	0.317
FD8-24	Control	0.183	0.314
FD8-25	Control	0.061	0.063
FD8-26	Control	0.066	0.142
FD8-27	Control	0.021	0.113
FD8-28	Control	0.053	0.289
FD8-29	Control	0.114	0.238
FD8-30	Control	0.105	0.146
FD8-31	Control	0.101	0.237
FD8-33	Control	0.080	0.071
FD8-34	Control	0.140	0.117
FD8-35	Control	0.088	0.072
FD8-36	Control	0.081	0.089
FD8-37	Control	0.057	0.06
FD8-38	Control	0.104	0.111
FD8-39	Control	0.221	0.241
FD8-40	Control	0.237	0.265
FD8-41	Control	0.056	0.093
FD8-42	Control	0.184	0.273
FD8-43	Control	0.126	0.126
FD8-44	Control	0.193	0.092
FD8-45	Control	0.058	0.057
FD8-46	Control	0.183	0.23
FD8-48	Control	0.062	0.085
FD8-49	Control	0.134	0.247
Mean		0.113	0.157
SD		0.061	0.086
Mean +3SD		0.294	0.414
Sensitivity		23/23	20/23



January, July 23, 1953 10:42 A.M.

103

2022-1 user guide (11 x 1899) 638-3383

---

NETSCAPE

*E* *K* *N* *P* *S* *T* *V* *W* *Z*

WPS2024 FL

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

TTGCCAAGCTGAGGGCGGACCCGTAGTCATTCGGGCGGAACTCCCTCTTCGCGGGGGCTCGGAAAGGGGAGGACCCGCGGAAGGACTTCGGAAAGGGCGG  
1800  
TGGGGTTCTCATACCCGGCTGGGGATTCGGTACCCGGGGGATACCCGGGGAGGCGGGCGGAGGTTTCGGCTTCGGGGGGCTTCCTTCGAGCCTTTCGGGGCGG

HTCC-1 FL

28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100.

STOCK #3

卷之六

Sheet 2 of 2

Tuesday, July 28, 1998 10:43 AM  
TCC1(1,818) map.mpd (1 x 788) 538 ave. 889 1.28  
Infectious 212 of 818 enzymes (filtered)

HCC-1435- $\alpha$

三

Fig. 7a.

HICG-1U38-374

5

Wednesday, July 26, 1967 (Session 10:50 AM)

Sequence 212 of 318 enzymes (Pfam)

Fig. 7

HIC-3 (123)

三

Wednesday, July 26, 1995 10:48 AM  
TFC(111-123) Map.MPO (1 x 411) 3 100 sequences

ECO1 (M123) restriction endonucleases: All 513 enzymes (pro filters); Circular, Cetam, Siles Only; Standard Gels

Fig. 4c

Sunday, July 23, 1888 10:45 AM  
At Rockwood Park, (1/2 a mile from the lake)

KoBz-HJCC-1

三

FIG. 8  
Sheet 1 of 2

Fig. 6

Sheet 2 of 2

Wednesday, July 22, 1998 1:38 PM  
TEC11-10.1.mxd (1 > 1228) Site and S  
Surveyor 12 of 813 surveys (Planned)

HTCC-1 (Eq. 1)

三

Fig. 4a

FIG. 9a

100% Dose rate 0.5 > 112.8 Beta and Gamma

No 4111 measured 100% Gamma

Gamma


Lower Beta and Gamma Standard Gamma Cells

100%

Gamma

### T Cell Epitope Mapping of HTCC-1

Fig. 9c



654

Fig. 9.

Fig. 10

Monday, July 25, 1944 10:35 P.M.

Page 2

FIG. 10

Fig. 10

FIG.

Monday, July 26, 1999 2:42 PM  
201-149943-011-2000-mod-[1] 2000-07-26 14:42:00

四百三

Fig. 11

Monday, July 26, 1993 8:42 PM  
M11-149-HG-281 (111-112) and 113 [REDACTED] 115 and 200 116

100

fig. 1.

Fig. 12

FIG. 2

Fig. 12

三

Figure 1. Nucleotide sequence of MTb59

14

Figure 14: Amino acid sequence of MTbS9

MELTI PADDIQSAIEEYVGSFTADTSRSEEVTVVDAGDGIAHVECLPSVMTQELLEFFPGILGVA  
CNLDEKSVGAVILGDFENIEEGQQVKRTGEVLSVPVGDGFLCRVVNPLQQPIOGRCOVOSDTRRAL  
ELQAPSVVHRQGVKEPLQTGIKAIIDAMTPICRGQRQLIIGDKTKTAVCVDTILNQRQNWECDP  
KKQVRCVYVAICQKQGTITAAVRRTLEZCGAMDYTTIVAAAASESAGFENLAPYTGJAIACQHNMYEQ  
KHLVLIIPDOLTKQAEAYRAISLLLRRPPGREAKYPCDVFTYLHGRLLERCAKLSDQLOGGSLTGLPII  
ETKANDISAYIPTNVISTTDGQCSLETDLFNQQVVRPAINVGVSVSRVCGAAQIKAMXEVAGSLRLO  
LSQYRELEAFRAAFASDQDAASKGQLERCARLVELLKQPQSQPMVVEQVVSIFLGTGGHLDSPVVE  
DVRRRFETELLQHMRASEEEILTETIADSQKLPEGAADKLTENVCKNEKKGPAATQGGSVVPDERSV  
DEDKLAKEAIVKVKKPAPKKK

四

Figure 1. Nucleotide sequence of *Mfba2*.

16

Figure : Amino acid sequence of MTb82

MAKASETERSCPGTQPADAQTATSATVRYPLSTQAVFRPDFGDEDNFPHPTLCPOTEPQDRMATTER  
VRPPVRRILQQQLIVEIPRAPDIDPLEALMTNPVVPESKRFCNNCCRPVGRCSDSETKGASECWC9YCC  
SPYSFLPQLNPGDI VAGQYEVNGCIAANGLAMITYLALORNVNGRPPVVLKOLVHSGOAAQAQAMAMAE  
RQFLA2EVVHPSIVQIFPNFVHTD3HGDPCVYIVMEYVCGQSLKRSKCQKLPVAAAIAYLLEILPAL  
SYLKHSIGLVYNDLKPEENIMLTSEQLKLTIOLGAVSRINSFGYLYGTPGFQAPEIVRTGPTVATDIYT  
VGRTLAALTLDLPTRMGRYVOGLPEODPVLKTYDSYCRLLRRAIOPDPRQRPTTAEEMSAQLTCVL  
REVVAQDTGVPRPGUSTIPSPSRSTFGVULLVAHTDVYLDGQVHAEKLTANEIVTALSVPVLVOPTD  
VA&SVLQATVLSQPVQTLQSLRAARNGAADDQDFSESVELPLMEVRALLOLGDVAKATRKLDOL  
AERVGWRWRLVWYRAVABSLITGQYDSATKHFTEVLDTPFGELASKLALAATAELAGNTDENKFYQT  
VNSTNUGVI SAAFGALARARSAAEGDRVGAVRTLDEVPPTSRHFTTARLTSAVTLLSGRSTSEVTEEQ  
IRDAARRVEALSPTEPRVILQIRALVILGGALDWLKDNCASTNHILGFPTSHOLRLGVEASLRLAR  
VAFTQRHRYTLVDMANKVRFPTSTF.

17

Figure 11: Amino Acid Sequence of secreted DPPD

DPPDHNQPDNTKCYCPGGRNCFCOLAVCDGCKYPDGSFWHQHMQTWFTGPQFYFDCVSGCSEPLP  
GPPPPGCCGGAIPTSQPNAP

## SEQUENCE LISTING

## Mtb41 (MTCC#3)

## (2) INFORMATION FOR SEQ ID NO:140:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 141 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

|             |            |            |            |             |             |      |
|-------------|------------|------------|------------|-------------|-------------|------|
| CAGGTTTCTG  | CGATGGATT  | TGCGGCTTT  | ACCTCGGAA  | GTCGAATTCAA | CCCGAAATGTA | 60   |
| TTCCCGTGG   | CGCGCGGAGT | CGATGGTAGG | CCCGCCGCC  | GCCTGGGACG  | GTGCGGCCG   | 120  |
| CGAGCTTGACT | TCCGGGCGCG | TCTCGTATGG | ATCGCTGCTG | TGCAACCTGA  | TGCTTGAGCC  | 180  |
| GTGCGATGGG  | CCCGCGGTTG | CCCCGATGG  | GGCGCGGGCA | ACGGCGGTATG | TGCGCTGCTT  | 240  |
| GGCGCGGCCG  | GGCGCGGTTG | CGTACAGACG | GGAGGGCGCG | GGCGGGAAAGC | 300         |      |
| GTTCGGGACG  | GGCTTGTGAA | TCACCGTGG  | ACCATCCCTC | GTCGGGGCCA  | ACCCGAGCG   | 360  |
| CTTGTATGTTG | CTGCGCGCG  | CGAACATTCT | GGCGGAAAC  | AGTGCAGGAA  | TGCGCTGCTC  | 420  |
| CCAGGCGGAG  | TATGGGAAA  | TGTGGGGCA  | AGCGCTGGC  | GTCAGTACA   | GCTATGAGG   | 480  |
| GGCATCTGCG  | CCCCGTTGG  | CTTGGCGCG  | GTTCAGTCCA | CCCCGCGAG   | CCACCGGCC   | 540  |
| GGCGGGGCCG  | GGCGGGCGAG | CGCGGGCGAC | GGAGGGCGCC | GCTGGCGCG   | ACCTTGGGAA  | 600  |
| TGCGACGGG   | AGACTGGCCC | AGCTGGCGG  | GGGGATGCTG | ACCGACATTC  | TGCGCGAT    | 660  |
| GGCGGGCAAC  | GCTGATGGCG | TGACATGGG  | ATCGCTGCG  | CGCTCAAGC   | 720         |      |
| GCAAGTCGGA  | TCCGCTGCG  | CGATGCTGAT | CGCGACGGCG | ATAGGGGAAT  | TGCGCGTGT   | 780  |
| GGCGCTCTAC  | ATTCGATCCA | TGCGGACCG  | CGCGATTCG  | CTGCGATCA   | CGAACACGGC  | 840  |
| CAGACCGTGG  | CGACATGGCC | TTACGGGAA  | GGCGCGCG   | GTCGGACCGA  | CGCGGGGCGA  | 900  |
| TCCAGCTGACT | TCGGGACCGG | AGCGGGCGA  | CCCCGCTGG  | GGCGGGCGGC  | 960         |      |
| GGCGCTCTAC  | GGCGGCGCG  | GGCGGCGCG  | ATTAAGCGAA | GGCTTGTGCG  | TGCGCGACAG  | 1020 |
| CTGGACCCACG | GGCGGGCGCG | AGATCCGCT  | GGCGGTTGCG | GCAACACCC   | CTTCGAGCTC  | 1080 |
| CGAGGCGGGC  | GGCGGACCGA | GGCGGTTAA  | GGGGATCCG  | GCACGGCTCG  | TGCGCGAT    | 1140 |
| GGCTTGTGCG  | AGCGCTGGCG | CGACGCGAC  | GGCGGGCGT  | GGCGGCGCCC  | GTAGCGSCRC  | 1200 |
| CAGCACTGAC  | GGTCAAGAGC | AGGGCGCCAA | ACCGCTGTA  | TTTGTGATTA  | GGAGGCRGCG  | 1260 |
| GGCGGCGCGA  | AAACGGGGCG | GGTAAAGCTC | GGCGAACCGT | TGCTGGCGCG  | GGCGAAAATG  | 1320 |
| CCTGCTGAGC  | GTGGCTATCC | GAAGGGCGGT | TGACACCGGT | TGTGTGAGG   | TACGCGTATG  | 1380 |
| CGACGCGCTG  | TCTGGATCT  | CGCGGCTAT  | CGAGGCGATT | TGCTGGCGAA  | CTTCAGGCAA  | 1440 |
| G           |            |            |            |             |             | 1441 |

## (2) INFORMATION FOR SEQ ID NO:142:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 423 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asp | Phe | Gly | Leu | Leu | Pro | Pro | Glu | Val | Asn | Ser | Ser | Arg | Met | Tyr |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 1   |     |     |     |     |     |     |     | 5   |     |     |     |     |     | 10  | 15  |
| Ser | Gly | Pro | Gly | Pro | Glu | Ser | Met | Leu | Ala | Ala | Ala | Ala | Trp | Asp |     |

|   |     |     |     |
|---|-----|-----|-----|
|   | 20  | 25  | 30  |
| Gly Val Ala Ala Glu Leu Thr Ser Ala Ala Val Ser Tyr Gly Ser Val |     |     |     |
|   | 35  | 40  | 45  |
| Val Ser Thr Leu Ile Val Glu Pro Trp Met Gly Pro Ala Ala Ala Ala |     |     |     |
|   | 50  | 55  | 60  |
| Met Ala Ala Ala Ala Thr Pro Tyr Val Gly Trp Leu Ala Ala Thr Ala |     |     |     |
|   | 65  | 70  | 75  |
| Ala Leu Ala Lys Glu Thr Ala Thr Gln Ala Arg Ala Ala Glu Ala     |     |     | 80  |
|   | 85  | 90  | 95  |
| Ser Gly Thr Ala Phe Ala Met Thr Val Pro Pro Ser Leu Val Ala Ala |     |     |     |
|   | 100 | 105 | 110 |
| Asn Arg Ser Arg Leu Met Ser Leu Val Ala Ala Asn Ile Leu Gly Gln |     |     |     |
|   | 115 | 120 | 125 |
| Asn Ser Ala Ala Ile Ala Ala Thr Gln Ala Glu Tyr Ala Glu Met Trp |     |     |     |
|   | 130 | 135 | 140 |
| Ala Gln Asp Ala Ala Val Met Tyr Ser Tyr Glu Gly Ala Ser Ala Ala |     |     |     |
|   | 145 | 150 | 155 |
| Ala Ser Ala Leu Pro Pro Phe Thr Pro Pro Val Gln Gly Thr Gly Pro |     |     |     |
|   | 160 | 165 | 170 |
| Ala Gly Pro Ala Ala Ala Ala Ala Thr Gln Ala Ala Gly Ala Gly     |     |     |     |
|   | 175 | 180 | 185 |
| Ala Val Ala Asp Ala Gln Ala Thr Leu Ala Gln Leu Pro Pro Gly Ile |     |     |     |
|   | 190 | 195 | 200 |
| Leu Ser Asp Ile Leu Ser Ala Leu Ala Ala Asn Ala Asp Pro Leu Thr |     |     |     |
|   | 210 | 215 | 220 |
| Ser Gly Leu Leu Gly Ile Ser Thr Leu Asn Pro Gln Val Gly Ser     |     |     |     |
|   | 225 | 230 | 235 |
| Ala Gln Pro Ile Val Ile Pro Thr Pro Ile Gly Glu Leu Asp Val Ile |     |     | 240 |
|   | 245 | 250 | 255 |
| Ala Leu Tyr Ile Ala Ser Ile Ala Thr Gly Ser Ile Ala Leu Ala Ile |     |     |     |
|   | 260 | 265 | 270 |
| Thr Asn Thr Ala Arg Pro Trp His Ile Gly Leu Tyr Gly Asn Ala Gly |     |     |     |
|   | 275 | 280 | 285 |
| Gly Leu Gly Pro Thr Gln Gly His Pro Leu Ser Ser Ala Thr Asp Glu |     |     |     |
|   | 290 | 295 | 300 |
| Pro Glu Pro His Trp Gly Pro Phe Gly Gly Ala Ala Pro Val Ser Ala |     |     |     |
|   | 305 | 310 | 315 |
| Gly Val Gly His Ala Ala Leu Val Gly Ala Leu Ser Val Pro His Ser |     |     | 320 |
|   | 325 | 330 | 335 |
| Trp Thr Thr Ala Ala Pro Glu Ile Gln Leu Ala Val Gln Ala Thr Pro |     |     |     |
|   | 340 | 345 | 350 |
| Thr Phe Ser Ser Ala Gly Ala Asp Pro Thr Ala Leu Asn Gly Met     |     |     |     |
|   | 355 | 360 | 365 |
| Pro Ala Gly Leu Leu Ser Gly Met Ala Leu Ala Ser Leu Ala Ala Arg |     |     |     |
|   | 370 | 375 | 380 |
| Gly Thr Thr Gly Gly Gly Ile Arg Ser Gly Thr Ser Thr Asp Gly     |     |     |     |
|   | 385 | 390 | 395 |
| Gln Glu Asp Gly Arg Lys Pro Pro Val Val Val Ile Arg Glu Gln Pro |     |     | 400 |
|   | 405 | 410 | 415 |
| Pro Pro Gly Asn Pro Pro Arg                                     |     |     |     |
|   | 420 |     |     |

## Mtb40 (HTCC#1)

(2) INFORMATION FOR SEQ ID NO:137:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1200 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

|                        |             |             |             |             |      |
|------------------------|-------------|-------------|-------------|-------------|------|
| CAGCCATGAG CAGACCGTTTC | ATCATGGATC  | CAAAGATCAAG | TGCCATTGAC  | GCTTGTACG   | 60   |
| ACCTTCTGCG             | CATTGCGATA  | CCCACCCAAAG | GGGTATCTCT  | TTACTCTCTCA | 120  |
| TGAAARAAAGC            | CCTGGAGGGAG | CTGGCACCGAG | CGTTTCCCGG  | TGATGCGCTCG | 180  |
| CCGGCGACAA             | ATACCGCCGC  | AAAACCCCA   | ACACAGTGA   | TTTTTTCCAG  | 240  |
| ACCTTGATCG             | TGAGCTCA    | ACCTGATCC   | ACGACCCAGGC | CAACCCGTC   | 300  |
| GGGACATGTT             | GGGGCGCCG   | AAGRAAGGTC  | TGAGCTTCT   | GGGGCGGTG   | 360  |
| TGACCTTACAT            | GGGGGTGTC   | GGGGACCCCC  | TATGGCCCG   | CTTCCAGGCG  | 420  |
| CGGGCGCGAT             | GGGGTGTG    | GGGGGGGGCG  | TTGGCTACTT  | GTTGGTGA    | 480  |
| ACGGGACTCA             | ACTGCTCAA   | TTGCTTGGCA  | ATTTGGCGA   | GTGGGTGCG   | 540  |
| GGGACATCAT             | TTGGGATGTC  | GGGGACATCA  | TCAAGGGGNC  | GTGGGAGAA   | 600  |
| TCATCRAAA              | GGGGCTCAAC  | GGGGCTGAAAG | AGCTTTCGGA  | CAAGCTCA    | 660  |
| CGGGGACTTT             | CTCTCGACCG  | TGGTGGAC    | TGAGCTCTTT  | CTTTCGCGGC  | 720  |
| TAACGGGCGC             | GGGGGGTC    | TTGGGCGAG   | TAACGGCTT   | GTGGGGTGG   | 780  |
| GGGGATGTC              | GGGGTTGGCT  | GGGGGGATA   | GGCTGGGGAG  | CTCAGCCAGC  | 840  |
| GGGGGGCAT              | TGGGGGCTTG  | GGGGGGTTTG  | GGGGCTTGC   | GGGGCTGGCT  | 900  |
| GGGGCTCAAC             | TGGGGGCTG   | GGGGGGCTCT  | GAGGTAATGG  | GGGGGGGGCG  | 960  |
| AGGGGGTGG              | GGGGGGCTCG  | GGGGGGGGCG  | TTGGGGGAT   | ATGGGGGGAG  | 1020 |
| GGGGGGCAT              | GGGGGGGATG  | GGGGGGCTT   | GGGGGGGTC   | GAAGGGGAGG  | 1080 |
| AGTACTTGA              | AGGGGGGGCG  | GGGGGGCTG   | AAGACCCGGGA | GGGGGGGCGCA | 1140 |
| ACGGGGGGGG             | TGGGGGGAAAG | GTGGGGTAC   | TAACGGGGAT  | GGGGGGCGCA  | 1200 |

## (2) INFORMATION FOR SEQ ID NO:118:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 393 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

|   |     |     |    |  |
|---|-----|-----|----|--|
| Met Ser Arg Ala Phe Ile Ile Asp Pro Thr Ile Ser Ala Ile Asp Gly |     |     |    |  |
| 1   | 8   | 10  | 15 |  |
| Leu Tyr Asp Leu Leu Gly Ile Gly Ile Pro Asp Gln Gly Gly Ile Leu |     |     |    |  |
| 20  | 28  | 30  |    |  |
| Tyr Ser Ser Leu Glu Tyr Phe Glu Lys Ala Leu Glu Leu Ala Ala     |     |     |    |  |
| 35  | 40  | 45  |    |  |
| Ala Phe Pro Gly Asp Gly Trp Leu Gly Ser Ala Ala Asp Lys Tyr Ala |     |     |    |  |
| 50  | 55  | 60  |    |  |
| Gly Lys Asn Arg Asn His Val Asn Phe Phe Gln Glu Leu Ala Asp Leu |     |     |    |  |
| 65  | 70  | 75  | 80 |  |
| Asp Arg Gln Leu Ile Ser Leu Ile His Asp Gln Ala Asn Ala Val Gln |     |     |    |  |
| 85  | 90  | 95  |    |  |
| Thr Thr Arg Asp Ile Leu Glu Gly Ala Lys Lys Gly Leu Glu Phe Val |     |     |    |  |
| 100   | 105 | 110 |    |  |

4

Arg Pro Val Ala Val Asp Leu Thr Tyr Ile Pro Val Val Gly His Ala  
 115 120 125  
 Leu Ser Ala Ala Phe Gln Ala Pro Phe Cys Ala Gly Ala Met Ala Val  
 130 135 140  
 Val Gly Gly Ala Leu Ala Tyr Leu Val Val Lys Thr Leu Ile Asn Ala  
 145 150 155 160  
 Thr Gln Leu Leu Lys Leu Ala Lys Leu Ala Glu Leu Val Ala Ala  
 165 170 175  
 Ala Ile Ala Asp Ile Ile Ser Asp Val Ala Asp Ile Ile Lys Gly Thr  
 180 185 190  
 Leu Gly Glu Val Trp Glu Phe Ile Thr Asn Ala Leu Asn Gly Leu Lys  
 195 200 205  
 Glu Leu Trp Asp Lys Leu Thr Gly Trp Val Thr Gly Leu Phe Ser Arg  
 210 215 220  
 Gly Trp Ser Asn Leu Glu Ser Phe Phe Ala Gly Val Pro Gly Leu Thr  
 225 230 235 240  
 Gly Ala Thr Ser Gly Leu Ser Gln Val Thr Gly Leu Gln Gly Ala Ala  
 245 250 255 260  
 Gly Leu Ser Ala Ser Ser Gly Leu Ala His Ala Asp Ser Leu Ala Ser  
 265 270  
 Ser Ala Ser Leu Pro Ala Leu Ala Gly Ile Gly Gly Ser Gly Phe  
 275 280 285  
 GLY Gly Leu Pro Ser Leu Ala Gln Val His Ala Ala Ser Thr Arg Gln  
 290 295 300  
 Ala Leu Arg Pro Arg Ala Asp Gly Pro Val Gly Ala Ala Glu Gln  
 305 310 315 320  
 Val Gly Gly Gln Ser Gln Leu Val Ser Ala Gln Gly Ser Gln Gly Met  
 325 330 335  
 Gly Gly Pro Val Gly Met Gly Gly Met His Pro Ser Ser Gly Ala Ser  
 340 345 350  
 Lys Gly Thr Thr Thr Lys Lys Tyr Ser Glu Gly Ala Ala Gly Thr  
 355 360 365  
 Glu Asp Ala Glu Arg Ala Pro Val Glu Ala Asp Ala Gly Gly Gly Gln  
 370 375 380  
 Lys Val Leu Val Arg Asn Val Val  
 385

### Mtb9.9A (MTI-A)

#### (2) INFORMATION FOR SEQ ID NO:3:

##### (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1742 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CCGCTCTCTT TCAACGTCAT AAGTTCCGTC CGCGACTCGG CGCGCGCTGC ATATGGCACC  
 AATAACGGGT GTCCCCATGGA TACCCGGACCC CGACGGACGCT AGACGCCGATC AGCGCGACCG

69

129

|              |             |             |             |             |            |      |
|--------------|-------------|-------------|-------------|-------------|------------|------|
| CTGGCGGAACCA | CTAACCGGTC  | CACCGCTTCCC | CCCTCCCCCT  | TCCCGAAGAT  | CGACGTCAGG | 160  |
| TTCTCTATGCT  | CTTTAACGCC  | TTCCCAACACT | CGCGACGGTGC | GGGGGGCGGC  | GACCACGTGA | 240  |
| SCAAAGCTCG   | CTTCCCCCAC  | CCGGGCGCGG  | CTCTCCAAACA | CCCCACGATT  | GAGATGGAA  | 320  |
| CCGGATCAGCC  | CTGCCATGAC  | ATCGGGGAC   | CTCTGATACT  | ACGGGGGGCC  | GACGGGGCC  | 400  |
| AGATCATCT    | TGAGCTCGGC  | CAAGGGGGCG  | TCCGTCGGGA  | ACAGGGCCAG  | CGCGCTCAG  | 480  |
| CGTGAGGCCA   | CGATGCGCTG  | CACCGAGG    | ACACCGCTCG  | CGCTTACCAA  | CGCTTTCGCG | 560  |
| CTCGCGAGAT   | CGGACNACN   | CTCGATGCTG  | TTGAGCTCAC  | CGAAATCGTC  | GAAGCTTGG  | 640  |
| TCCGCGGAT    | CGAGAGCGTC  | CTGAACATCG  | AGGGCGTCGG  | GGTGGCTGGG  | ACAGACGGCT | 720  |
| TCGGTCACCG   | CTTTTCGCG   | ACCGACGCCA  | CGATCGAGTC  | GGGGCGCTG   | CGCAGGATCT | 800  |
| CAAGCTCGCT   | CGCGTTCAAGC | CTGCGGCC    | CGTCAGCCAG  | CGACTCTTC   | AGAGAGCCGT | 880  |
| TGCTGGATT    | AATTCGGAGA  | CGAACAGAGC  | ATGTCGTTG   | TCACCAACACA | GGCGGAAGCC | 960  |
| CTGCGAGCTG   | CGCGGGCGAA  | CTTACAGCT   | ATTCGACCGA  | CGATGAGGC   | CGAGAACCGC | 1040 |
| GGCGCGGCTG   | CTTCGACCCAC | CGAGCTA     | CGCGCGCCG   | CGGATGAACT  | ATCAACGCTG | 1120 |
| ACCGCGGCTG   | ATTTTCGCTG  | CGACCGCGAG  | ATGATCCAAA  | CGGTAGCGC   | CGAGCGCCCG | 1200 |
| CGCATTCACG   | AAATGTTGCT  | GAACCGCTG   | CTGCGCACTT  | CTGGCTCAT   | CGCGGCCACC | 1280 |
| GAAGCGGCCA   | ACGGCGGCCG  | TGCGCGCTG   | ACCGCTCGC   | ACGAACTTC   | TGAGGGAGA  | 1360 |
| GGGAAACATC   | CGGAGTTCTG  | GGGTACCGG   | TTCTTCCAGC  | GGCGAGCGCA  | TTGAGNTATC | 1440 |
| GGCGTCCATA   | ACACGAGACG  | ATTTAGCGAT  | TCAGTACTAA  | CGAGACAGGC  | AACATGGGCT | 1520 |
| CACTTTTAT    | GAACGGATCG  | CTACCGATCG  | GGGACATGGC  | GGGGCGTTT   | GAAGTGCAGG | 1600 |
| CCGAGACGCT   | GGACGACCGAG | CTCTGCCCGA  | TGTTGGCTG   | CGCGCAAAAC  | ATTTCGCTG  | 1680 |
| CGGCGCTGGAG  | TCCTCATGCC  | GGGGCCACCT  | CGTAGACAC   | CATGACCTAC  | ATGAATCGGG | 1760 |
| CGTTTCCGAA   | CATCGTGCAC  | ATGCTGCG    | GGTGGCGTGA  | CGGGCTGTT   | CGCGACGGCA | 1840 |
| ACAAATGCGA   | ACACGAGAGC  | CGGGCTCCG   | ACGAGATCT   | CGACGAGTTG  | CGCCGAANG  | 1920 |
| CAACGCTGAG   | TACGTTTCT   | CTACATTAGA  | GAACACCAAT  | ATGAGGATTA  | ATTACCGATT | 2000 |
| GGGGGACGTC   | GAACGCTGAT  | CGCGCGAT    | CGCGCTCGA   | GGGGCGCTG   | TTGAGCGCGA | 2080 |
| CGATCAGGCC   | ATGTTTCTG   | ATGTTTCTG   | GGGGCGTGC   | TTTTGGGGCG  | GGGGCGGTTC | 2160 |
| CGTGGCTTGC   | CAACGAGTCA  | TTACCCAGTT  | GGGGCGTAAC  | TTCCAGGTTA  | TCTACGCGCA | 2240 |
| CG           |             |             |             |             |            | 2320 |

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2836 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

|             |            |             |            |             |            |     |
|-------------|------------|-------------|------------|-------------|------------|-----|
| CTGATTTGCG  | TTGGCGCGCG | GGGGGAAAGAC | CAACGACTCG | CTGGGGGTGC  | TGACACAGGC | 60  |
| CGTGGCGTGC  | CTGAGCTGCC | CGAAATCCCAA | TGATTTGCG  | CTGAGTTCGGG | TTGCTGGCT  | 120 |
| CGATTACCGCC | CAACGAAAGG | ACGACGATCG  | TTGGTTTCT  | CGGTCACTGCG | TACTTGGCGA | 180 |
| CGCGCGATCG  | CGGGTTTCTT | ACGCGATCG   | CGACCGAGCT | GAACGTTCCGC | CGAGGGCGCA | 240 |
| CAACGCGTGC  | CTCCGCGCGA | CGCTGCTACC  | CAACGCGCA  | ATTCGCGCGC  | CTGGGTCACG | 300 |
| CGGCGCGCT   | CTGGGCGGAT | TTGGCGCGG   | CGGAGCGCGT | CGGGAGTTG   | TCGGTGGCGC | 360 |
| CGAATTCGCG  | CTGGGCGGAT | CGGAGCGCGT  | CGGGAGTTG  | TCGGTGGCGC  | ACGGGAGATG | 420 |
| CGAATTCGCG  | CTGGGCGGAT | CGGAGCGCGT  | CGGGAGTTG  | TCGGTGGCGC  | ATACCGCTGC | 480 |
| CGGTCATCGG  | CGAAGCGCTG | AGCTGGCTGC  | AGGGAGCGCT | CGTTCGAGGC  | ATACCGCTGC | 540 |
| CGAGACCGGG  | GGGGCGTACA | GGGGCGTACA  | CTACCGATA  | CGGGTTCCGC  | CAACGCGTGA | 600 |
| TTACCCGGTC  | TCCTCTGGCG | GGATAGCTTT  | CGATCGCGTC | TCGGGCGCGG  | CGCGAAATGC | 660 |
| TCACAGATCG  | GATGACCGCC | GGGGCGTGT   | AAACGGCGCA | CAACGCGACTA | TCAATGCCCA | 720 |
| CGGCGCGCT   | TCATGCCGAA | TTGACCGCTC  | CGACGCGCT  | TTATCTCGG   | CGAGATTTCA | 780 |
| TCGGGCGCGC  | CGTGGTGGG  | CCGATAATA   | CGCTGGTCA  | CGGGCTGATT  | CGGGCTGAAT | 840 |

三

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| TGATATCTCT  | GGCGCGGTCT  | TGAGACGCCGA | GTTATCTCGAG | TGGGGCCCAA  | ACCGGCTTCAA | 840  |
| ACGCTTCTTAC | TTCGCGTTA   | CCACCGTGTGA | ATTTCGGGTTG | CCAACCTGTTG | AACACTTCCC  | 900  |
| AACTGGTGGC  | ATCGAAATCA  | ACTTGTTCG   | TTTCAGTGAT  | CTACTCTTCTT | CGAGAGANCC  | 960  |
| TTTGCTGGG   | TTAATTGGG   | GAAGGAGACA  | GCATGTCGTT  | CCTGACCA    | CGGGGGAGAC  | 1020 |
| CCCTGCAGC   | TGGGGGGGGG  | AACTTACAGG  | GTATTGGCAC  | CGCATGAAAC  | GGCCGAGAAC  | 1080 |
| CCCCCTGCG   | TGCTCCAAACC | ACCGGATTCG  | TGCCCCGAGG  | GGCCGATGAA  | GTTACAGCCC  | 1140 |
| TGACCGGGG   | TGTTTTGCT   | GGCGACCGTC  | AGATTTACCA  | AACCGTACCC  | GGCGGGGCCC  | 1200 |
| CUGGCAATTCA | CGAAATGTTG  | GTAAACAGG   | TGCTGGCCAG  | TTCTGGCTCA  | TACCGGGGCA  | 1260 |
| CGGAGTCGGG  | CAACCGACCC  | GTGTTGGCT   | GAACGGGCTC  | CCACGAAACCT | CTTCAGGGAG  | 1320 |
| ACGGGAAACA  | TGCGGAGTTG  | TCGAGTCAAG  | GGTTCGCGCA  | GCACCTCAGCC | GATTTCAGCTA | 1380 |
| TGCGGTGCA   | TAACAGGAGA  | CGATCTAGG   | ATTAGTACT   | AACTGAGACG  | CGAACATGEC  | 1440 |
| CTTCACGTTT  | ARGACGGGATC | GGCATTCGGAT | GGCGAACATG  | GGGGGGGCGT  | TTGAGGCTCA  | 1500 |
| CCCCACACG   | GTGGAGGAGG  | AGGCTGCGCG  | GTGTTGGCG   | TGGGCGCIAA  | ACATTTCCGG  | 1560 |
| TGCGGCTG    | AGTGGGATCG  | CGGAGGCGAC  | TCTCGTAGAC  | ACCATAACCT  | AGATGAACTA  | 1620 |
| GGCGTTTCCG  | AACATGCTTA  | ACATGCTGCA  | CGGGTGGCT   | GGGGGGCTGG  | TTGCGGACCC  | 1680 |
| CAACAACTAC  | GAACAGGAG   | AGCAGGCTC   | CGAGCAGTC   | CTGAGGAGCT  | AGCCCGGAAA  | 1740 |
| GGCACAGCTG  | CGTACGTTT   | CTTCACATTAG | GACAACACCA  | ATATGACGAT  | TTATTACCG   | 1800 |
| TTGCGGACG   | TGACCGCTCA  | TGGCGCCATG  | ATTGGCGTC   | AGGCGGCGTC  | GGTTGAGGCG  | 1860 |
| GAGGTCAGG   | CGATGTTTCG  | TGATGTTTG   | GGGGGGGCG   | ACTTTTGCGG  | GGGCGCGGTT  | 1920 |
| TGCGTGGCTT  | GGCGGGAGTT  | CATTACCCAG  | TTCGGCCGTA  | ACTTCGAGCT  | GATCTACCG   | 1980 |
| CAACAGAGTA  | CGCGCACCGG  | CATCGCGTC   | AACTGCGAGC  | GCTTCGCGAT  | GGCGACCTGAC | 2040 |
| CTACTGGATA  | TCCCGAACGT  | TGCGCTGAG   | TTACGTTGCT  | GGCGTACGCT  | ACGGCGACCA  | 2100 |
| TCCATGACT   | GGCTTAAAGCA | TGAACTTGG   | TGCGCGGAGC  | ACGGCGACCA  | ACGGCGACCA  | 2160 |
| CTCAAAAGACG | CGGTCAACCA  | ACAGGTTCT   | GGCGGGATGA  | AGCTTCCTTC  | CGCGACCTGAT | 2220 |
| CTTCGAACTCG | TGCGCTGCT   | CTGACCGCGC  | AACTTGTCTG  | GGTTGAGGCG  | GGCGACCTGAT | 2280 |
| ACCGAGCGCC  | CGAGTTTCCG  | TGACGTCGCT  | GGCGTACGCT  | CTGGCGACCA  | GGCGACCTGAT | 2340 |
| CGAGGCGAGC  | ACTGGGTTTC  | GGGGTACGG   | CTTGGCAATG  | ACATCGACGT  | CGATGACGTC  | 2400 |
| AGGTTCTCGA  | ATAGGGCGCTC | GTACGGCGCA  | CTGGTAAATG  | AGCTTCCTTC  | CGCGACCTGAT | 2460 |
| CAACCGCGAC  | CGAGGGGAGAT | GAACGGCTC   | AACTGCGAGA  | TGAGGAGAT   | CTGCGTCCGGA | 2520 |
| ATTGGCGACG  | AGGCGACGAG  | CGTGTGGT    | GGCGAGGCGA  | TCGATCACCA  | TCATGACCG   | 2580 |
| GGCGGAGATC  | TTGGGGATTT  | GGTTCAGCAC  | GAACCGGGCC  | GGGGGGGAGC  | TCTGGGACAT  | 2640 |
| CCATGGGTTG  | TTCCCG      |             |             |             |             | 2700 |

(a) INFORMATION FOR SEQ ID NO:29:

#### (ii) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 94 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(44) MOLECULE TYPE: peptide

(v) ORIGINAL SOURCE:

- (3) ORGANISM: *Mycobacterium tuberculosis*

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Ala Cys Gln Gly Phe Ile Thr Gln Leu Gly Arg Asn Phe Gln Val Ile  
 50 55 60  
 Tyr Glu Gln Ala Asn Ala His Gly Gln Lys Val Gln Ala Ala Gly Asn  
 65 70 75 80  
 Asn Met Ala Gln Thr Asp Ser Ala Val Gly Ser Ser Trp Ala  
 85 90

### Mtb9.9A (MTI-A) ORF peptides

#### (2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Met Thr Ile Asn Tyr Gln Phe Gly Asp Val Asp Ala His Gly Ala  
 5 10 15  
 1

#### (2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Gln Phe Gly Asp Val Asp Ala His Gly Ala Met Ile Arg Ala Gln  
 5 10 15  
 1

#### (2) INFORMATION FOR SEQ ID NO:53:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Asp Ala His Gly Ala Met Ile Arg Ala Gln Ala Ala Ser Leu Glu  
1                   5                                   10                           15

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Met Ile Arg Ala Gln Ala Ala Ser Leu Gln Ala Glu His Gln Ala  
1                   5                                   10                           15

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Ala Ala Ser Leu Glu Ala Gln Ala Ile Val Arg Asp Val  
1                   5                                   10                           15

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Ala Glu His Cln Ala Ile Val Arg Asp Val Leu Ala Ala Gly Asp  
1                   5                   10                   15

## (2) INFORMATION FOR SEQ ID NO:57:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Mycobacterium tuberculosis

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

Ile Val Arg Asp Val Leu Ala Ala Gly Asp Phe Trp Gly Gly Ala  
1                   5                   10                   15

## (2) INFORMATION FOR SEQ ID NO:58:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Mycobacterium tuberculosis

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

Leu Ala Ala Gly Asp Phe Trp Gly Gly Ala Gly Ser Val Ala Cys Gln  
1                   5                   10                   15

## (2) INFORMATION FOR SEQ ID NO:59:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Mycobacterium tuberculosis

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Phe Trp Gly Gly Ala Gly Ser Val Ala Cys Cln Glu Phe Ile Thr  
1                   5                   10                   15

## (2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

#### (4.1) MOLECULE TYPE: peptides

(vii) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Gly Ser Val Ala Cys Gin Glu Phe Thr Thr Gln Leu Gly Arg Asn  
15 16

(2) INFORMATION FOR SEQ ID NO:61:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
- (B) TYPE: amino acid
- (C) STRANGENESS: single
- (D) TOPOLOGY: linear

(iii) MOLECULE TYPE: Peptides

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

(2) INFORMATION FOR SEQ ID NO:63:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(iii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

Arg Asn Ser Gln Val Ile Tyr Glu Gln Ala Asn Ala His Gly Gln  
10 15

(3) INFORMATION FOR SEQ ID NO:63:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 amino acids

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Ile Tyr Glu Gln Ala Asn Ala His Gly Gln Lys Val Gln Ala Ala  
1                   8                   10                   15

(2) INFORMATION FOR SEQ ID NO:64:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

Asn Ala His Gly Gln Lys Val Gln Ala Ala Gly Asn Asn Met Ala  
1                   8                   10                   15

(2) INFORMATION FOR SEQ ID NO:65:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Lys Val Gln Ala Ala Gly Asn Asn Met Ala Gln Thr Asp Ser Ala  
1                   8                   10                   15

(2) INFORMATION FOR SEQ ID NO:66:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

七

### **MOLECULAR TYPES: Part 2**

(will originate from SOURCE)

(A) ORGANISM: *Mycobacterium tuberculosis*

(xii) SENTENCE DESCRIPTION: SEQ 13 NO:65:

Arg Asn Asn Met Ala Glu Thr Arg Ser Ala Val Gly Ser Ser Tyr Ala  
10 15

### Mtbe's OMSL

(a) INFORMATION FOR EFO ID NO. 12:

#### LINE SEQUENCES CHARACTERISTICS:

(3) LENGTH: 200 METERS

### **ANSWER: ANALYSIS SECTION**

ANSWER: **South**

11.2. *Non-convex curves*, *Part I* (continued)

### 1.3.1. Contaminant sources

#### ORGANEN: *Leishmania* subg. *leishmania*

(cont.) sequence presentation, SEQ ID NO:12:

|             |             |              |             |             |             |     |
|-------------|-------------|--------------|-------------|-------------|-------------|-----|
| TGCAATTCCGA | TACCGGTTTC  | GGCCCCCTCGA  | CCCGGGACCA  | GGGGGGCGCG  | GCCTCCGAAC  | 64  |
| GGGGGGCGCG  | CACGCTGGGA  | TTGGGGGGGA   | CCGGAAACCA  | AAGAACGGCGG | GTCGGGGGGG  | 128 |
| TCCGGGCTGAC | CCGACTGCGC  | GATGATGTAATG | TGTGCGACGG  | CCCCCGGATG  | CGATGGCTGC  | 180 |
| CGGGGGACCTG | CGACGAGGCC  | AGCAACGRCG   | CGAAGGGGCC  | CGACGGATCG  | GGAGAGGGCG  | 240 |
| GGGGGGACCTG | CTTACCGCAC  | GAACGGAACT   | AACCGGATTC  | CGAATCGCTT  | GGACCCGTAC  | 300 |
| GGGTGCGAAG  | CAGAGATGTT  | ATGGGGCTTT   | TGGATGCTCA  | TATCCCACAG  | TTCGTTGGCT  | 360 |
| CCGAGTCGCG  | CTTTCGGCGCC | AAAGGGGGGC   | TCATGCGGCCA | CAAGGATCGT  | CGGGCCGAGC  | 420 |
| AGGGGGGGAT  | CTCGGGTCAG  | GGGTGTCACC   | AGGGGGGASTC | GTGGGGCGCG  | TTTCAGGGCG  | 480 |
| CCCATGGCCG  | GTGTTGTCAG  | GGGGGGGGCA   | AAAGTCACACG | CTTGTTGGAT  | GTGGGGCGAGG | 540 |
| CGAATTCGGG  | TGAGGGGGCC  | GGTAACTATG   | TGGGGGGCGA  | TGCTG       |             | 585 |

(3) INFORMATION FOR SEC ID NO: 109:

### 4.3 SEQUENCES CHARACTERISTICS

(a) *Leucine*: 82 amino acids

卷之三

ANSWER: **WATER**

...not even a year, proportion

4-43. CONCURRENCE APPROVALS: SEE ID NO. 109.

Met Ser Leu Leu Asp Ala His Ile Pro Gln Leu Val Ala Ser Gln Ser  
 1                       5                       10                       15  
 Ala Phe Ala Ala Lys Ala Gly Leu Met Arg His Thr Ile Gly Gln Ala  
 20                       25                       30  
 Ala Gln Ala Ala Met Ser Ala Gln Ala Phe His Gln Gly Glu Ser Ser

|   |    |    |
|---|----|----|
| 35  | 40 | 45 |
| Ala Ala Phe Gln Ala Ala His Ala Arg Phe Val Ala Ala Ala Ala Lys |    |    |
| 50  | 55 | 60 |
| Val Asn Thr Leu Leu Asp Val Ala Gln Ala Asn Leu Gly Glu Ala Ala |    |    |
| 65  | 70 | 75 |
| Gly Thr Tyr Val Ala Ala Asp Ala Ala Ala Ser Thr Tyr Thr Gly     |    |    |
| 85  | 90 | 95 |
| Phe   |    |    |

**Mtb9.8 ORF peptides**

## (2) INFORMATION FOR SEQ ID NO:110:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

|   |   |    |    |
|---|---|----|----|
| Met Ser Leu Leu Asp Ala His Ile Pro Gln Leu Val Ala Ser Gln |   |    |    |
| 1   | 5 | 10 | 15 |

## (2) INFORMATION FOR SEQ ID NO:111:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

|   |   |    |    |
|---|---|----|----|
| Ala His Ile Pro Gln Leu Val Ala Ser Gln Ser Ala Phe Ala Ala |   |    |    |
| 1   | 5 | 10 | 15 |

## (2) INFORMATION FOR SEQ ID NO:112:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

|   |   |    |    |
|---|---|----|----|
| Leu Val Ala Ser Gln Ser Ala Phe Ala Ala Lys Ala Gly Leu Met |   |    |    |
| 1   | 5 | 10 | 15 |

## (2) INFORMATION FOR SEQ ID NO:113:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

Ser Ala Phe Ala Ala Lys Ala Gly Leu Met Arg His Thr Ile Gly  
1                       5   10                                   15

## (2) INFORMATION FOR SEQ ID NO:114:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

Lys Ala Gly Leu Met Arg His Thr Ile Gly Gln Ala Glu Gln Ala  
1                       5                                   10                           15

## (2) INFORMATION FOR SEQ ID NO:115:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

Arg His Thr Ile Gly Gln Ala Glu Gln Ala Ala Met Ser Ala Gln  
1                       5                                   10                           15

## (2) INFORMATION FOR SEQ ID NO:116:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

Gln Ala Glu Gln Ala Ala Met Ser Ala Gln Ala Phe His Gln Gly

三

六

1

三〇

二〇

(2) INFORMATION FOR SEQ ID NO:117:

### (a) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

MOLECULE TYPE: peptides

(x4) SEQUENCE DESCRIPTION: SEQ ID NO:117:

Ala Met Ser Ala Gln Ala Phe His Gln Gly Glu Ser Ser Ala Ala  
1 2 3 4 5 6 7 8 9 10 11 12 13

(a) INFORMATION FOR SEQ ID NO:118:

### (ii) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(iii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

Ala Phe His Gln Gln Gly Ser Ser Ala Ala Phe Gln Ala Ala Ala His  
 10 11 12 13 14 15 16

(2) INFORMATION FOR SEQ ID NO:113:

#### III. SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(iii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

Ala Ser Ser Ala Ala Phe Gln Ala Ala His Ala Arg Phe Val Ala  
 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

(3) INFORMATION FOR SEQ ID NO:120:

### (3) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

Phe Gln Ala Ala His Ala Arg Phe Val Ala Ala Ala Ala Lys Val  
1                   5                   10                   15

## (2) INFORMATION FOR SEQ ID NO:121:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

Ala Arg Phe Val Ala Ala Ala Lys Val Asn Thr Leu Leu Asp  
1                   5                   10                   15

## (2) INFORMATION FOR SEQ ID NO:122:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

Ala Ala Ala Lys Val Asn Thr Leu Leu Asp Val Ala Gln Ala Asn  
1                   5                   10                   15

## (2) INFORMATION FOR SEQ ID NO:123:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

Asn Thr Leu Leu Asp Val Ala Gln Ala Asn Leu Gly Glu Ala Ala  
1                   5                   10                   15

## (2) INFORMATION FOR SEQ ID NO:124:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:134:

Мираж (ТЬН9)

(3) INFORMATION FOR SEC ID NO: 1063

### **3.1. SEQUENCES CHARACTERISTICS**

- (A) LENGTH: 3000 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:106:

|   |      |
|---|------|
| GCGGCTTAATCT TCCAGGTGAT CTACGGAGCAG CGCGAACGCC ACACGGCACAA CGTCGACGCT | 2230 |
| GCGGGCAACA ACATGGCGCA AACGGACAGC CGCGTGGCT CGAGCTGGGC CTGACACCAG      | 2340 |
| GCGAACCGCCA CGGAGCTGGT GTACCGACTGA AGTTCTCTCC CTGATCCTTC GCGTGGCACT   | 2450 |
| CTAACGCTC AGTCTGGG TGTGGTGGT TTGTGCTTG CGGGGTTCTT CGTGTCTGGT          | 2460 |
| CACTGCTGGT CGCGCTCGGG TGAGGACTTC GAGGCTAGG TAGGGCTTC CTTCGATCCA       | 2520 |
| TTCGCTGGT TGTGGGCGA CGACCGCTCC GAGGAGCGG ATGATCGAGG CGCGCTCGGG        | 2580 |
| GAAGATGCCCG AGGACCTGGG TTGGGCTCC TACCTCTCGG TTGAGGGGTT CCTGGGGGTT     | 2640 |
| GTGGAACCGA ATTTCGCGCC AGATCTCTTT CGGAAAGGG CGAAACGCCA CGACGCTGGT      | 2700 |
| CGCGGCGCTG CGAGGTGCT CGGCCACCC CGGAGCTTG CGGTGAGG CGTCGAGTAC          | 2760 |
| CGGATCATAT TGGGCAACAA CTGATTCCG CGGGGCTGG TGTAGATGG ACTGGCACCAG       | 2820 |
| CGTCGCGACG CGGGCCAGG AGGCGCTGG CGGGCTGGG ATCAGATGG CTGGCTAGTG         | 2880 |
| CGTTCGCGAG CGTCGCGAG CGGCTGGGG CGGGCTGGG CGGATCGGGG CCACCGAGGG        | 2940 |
| GGCGTGGGGG CGCTCTGGG CGGGCTGGG CGGGCTGGG CGGGCTGGG CGGGCTGGG          | 3000 |
| GAACAAACCCC AGCCAGCCCG CGGGCTGGG CGGGCTGGG CGGGCTGGG CGGGCTGGG        | 3060 |

## (2) INFORMATION FOR SEQ ID NO:107:

## (1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 191 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

|   |   |    |    |
|---|---|----|----|
| Met Val Asp Phe Gly Ala Leu Pro Pro Glu Ile Asn Ser Ala Arg Met |   |    |    |
| 1   | 5 | 10 | 15 |

|   |    |    |
|---|----|----|
| Tyr Ala Gly Pro Gly Ser Ala Ser Leu Val Ala Ala Ala Glu Met Trp |    |    |
| 20  | 25 | 30 |

|   |    |    |
|---|----|----|
| Asp Ser Val Ala Ser Asp Leu Phe Ser Ala Ala Ser Ala Phe Glu Ser |    |    |
| 35  | 40 | 45 |

|   |    |    |
|---|----|----|
| Val Val Trp Gly Leu Thr Val Gly Ser Trp Ile Gly Ser Ser Ala Gly |    |    |
| 50  | 55 | 60 |

|   |    |    |    |
|---|----|----|----|
| Leu Met Val Ala Ala Ala Ser Pro Tyr Val Ala Trp Met Ser Val Thr |    |    |    |
| 65  | 70 | 75 | 80 |

|   |    |    |
|---|----|----|
| Ala Gly Glu Ala Glu Leu Thr Ala Ala Glu Val Arg Val Ala Ala Ala |    |    |
| 85  | 90 | 95 |

|   |     |     |
|---|-----|-----|
| Ala Tyr Glu Thr Ala Tyr Gly Leu Thr Val Pro Pro Val Ile Ala |     |     |
| 100   | 105 | 110 |

|   |     |     |
|---|-----|-----|
| Glu Asn Arg Ala Glu Leu Met Ile Leu Ile Ala Thr Asn Leu Leu Gly |     |     |
| 115   | 120 | 125 |

|   |     |     |
|---|-----|-----|
| Gln Asn Thr Pro Ala Ile Ala Val Asn Glu Ala Glu Tyr Gly Glu Met |     |     |
| 130   | 135 | 140 |

|   |     |     |     |
|---|-----|-----|-----|
| Trp Ala Gln Asp Ala Ala Ala Met Phe Gly Tyr Ala Ala Ala Thr Ala |     |     |     |
| 145   | 150 | 155 | 160 |

|   |     |     |
|---|-----|-----|
| Thr Ala Thr Ala Thr Leu Leu Pro Phe Glu Glu Ala Pro Glu Met Thr |     |     |
| 165   | 170 | 175 |

Ser Ala Gly Gly Leu Leu Glu Gln Ala Ala Ala Val Glu Glu Ala Ser  
 180 183 186  
 Asp Thr Ala Ala Ala Asn Gln Leu Met Asn Asn Val Pro Gln Ala Leu  
 198 200 205  
 Gln Gln Leu Ala Gln Pro Thr Gln Gly Thr Thr Pro Ser Ser Lys Leu  
 210 215 220  
 Gly Gly Leu Try Lys Thr Val Ser Pro His Arg Ser Pro Ile Ser Asn  
 225 230 235 240  
 Met Val Ser Met Ala Asn Asn His Met Ser Met Thr Asn Ser Gly Val  
 245 250 255  
 Ser Met Thr Asn Thr Leu Ser Ser Met Leu Lys Gly Phe Ala Pro Ala  
 260 265 270  
 Ala Ala Ala Gln Ala Val Gln Thr Ala Ala Gln Asn Gly Val Arg Ala  
 275 280 285  
 Met Ser Ser Leu Gly Ser Ser Leu Gly Ser Ser Gly Leu Gly Gly  
 290 295 300  
 Val Ala Ala Asn Leu Gly Arg Ala Ala Ser Val Gly Ser Leu Ser Val  
 305 310 315 320  
 Pro Gln Ala Try Ala Ala Ala Asn Gln Ala Val Thr Pro Ala Ala Arg  
 325 330 335  
 Ala Leu Pro Leu Thr Ser Leu Thr Ser Ala Ala Glu Arg Gly Pro Gly  
 340 345 350  
 Gln Met Leu Gly Gly Leu Pro Val Gly Gln Met Gly Ala Arg Ala Gly  
 355 360 365  
 Gly Gly Leu Ser Gly Val Leu Arg Val Phe Pro Arg Pro Tyr Val Met  
 370 375 380  
 Pro His Ser Pro Ala Ala Gly  
 385 390

### Mtb32A (TbRa35)

#### (2) INFORMATION FOR SEQ ID NO:17:

##### (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1871 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

##### (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GACTACGTTG CTCAGAAAA ATGCTTGCCCG CGCGACCCCTT AAGGGCTGGGA CAATTTCTGA

60

|  |      |
|--|------|
| TAGCTACCCC GACACAGGAG CTTACGGGAT GACCAATTCC CCCCCCGGCT CACTCAGGTC    | 120  |
| CTCATGGTTG CTGAACTCTC TGGCTGCCGT CGCGCTGGGC CTGGCCACCG CGCCGGGCGA    | 130  |
| GGCGGCGCGG CGCGCGCTGT CGACAGGACG CTTACCCGAC TTCCCCCGCC TGCCCGTGA     | 140  |
| CGCGTACCGG ATGGTGGCCC AACAGTGTCGTC AACATCAACA CCAAACCTGG             | 150  |
| CTACACACAC CGCGTGGGG CGCGACGGG CAGCTCTCATC GATGCCAACG CTGTCTGCT      | 160  |
| GACCAACAAAC GAGTGATCG CGCGCGCACG AACATCAAT CGCTTCAACG TCGCGTCCG      | 170  |
| CCAAACCTAC CGCGTGTATG TGTCTGGTA TGTACCGACG CAGGATCTCG CGCTGCTCA      | 180  |
| CGTGGCGGT CGCGCGCGC TCGCGTCCG CGCGATCGGT CGCGCGCTCG CGTGTGGTGA       | 190  |
| CGCGCGTCG CGCGCGCGA ACAGCGCGCG CGAGCGCGA AGCGCGCGT CGCGCGCTCG        | 200  |
| CGCGCGTCG CGCGCGCGC AAACCGCTCA CGCGTGGAT TCGCTGACCG CGCGCGAAGA       | 210  |
| GACATTGAAAC CGCGTGTATCG ATTTGGATCG CGACATCGAG CGCGCGTATT CGCGCGCGCG  | 220  |
| CGTGTGTCAAC CGCGTACGGAC AGGTGGTCCG TATGACCGCG CGCGCGTCCG ATAACCTCCA  | 230  |
| CGTGTGTACG CGTGGCGAGG GATTCGCGAT CGCGATCGCG CGATCGCGCG CGCGCGCTCG    | 240  |
| CGAAATCCGA TCGCGTGGCG CGTCACCCAC CGTTCATATC CGCGCGTACCG CGTGTGTGCG   | 250  |
| CTTGGGTGTT CTGCGACACAA ACGGCAACCG CGCGCGACTCG CAAACCGCGT CGCGCGCGCG  | 260  |
| TGCGCGCGCA AGTCTCGCA TCTTACCGCG CGACCGTATC ACGGCGCGTCC ACGGCGCGTCC   | 270  |
| GATCAACTCG CGCGACCGCGA TGGCGACG CGTAAACCGG CGATCGCGCG CGACCGTATC     | 280  |
| CTCGGGTAAAC CGCGCGACCA AGTGTGGCGG CGACCGTACA CGGAACCGTGA CGTGGCGCGA  | 290  |
| CGGACCGCCCG CGCGCGATTC CGCGCGATAC CGCGCGCGCG CGCGCGCGATT CGATCGCGCG  | 300  |
| CGACCGGTGAT CGCGCGCGAT CGCGCGCGAT CGCGCGCGCG CGATCGCGCG CGATCGCGCG   | 310  |
| CGCAATGAAACG ACCGAGAAACA CGCGCGTACG CGACCGTACCG CGTGGCGCG CGCGCGCGCG | 320  |
| GGCGCGGTGCG CGACCGCGATCC CGATCGCGAG GACTCGCGA CGCGCGCGCG CGCGCGCGCG  | 330  |
| CGATCGCGACG CGTGTGACCA CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGAC   | 340  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 350  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 360  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 370  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 380  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 390  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 400  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 410  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 420  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 430  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 440  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 450  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 460  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 470  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 480  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 490  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 500  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 510  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 520  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 530  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 540  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 550  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 560  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 570  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 580  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 590  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 600  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 610  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 620  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 630  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 640  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 650  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 660  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 670  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 680  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 690  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 700  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 710  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 720  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 730  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 740  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 750  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 760  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 770  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 780  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 790  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 800  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 810  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 820  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 830  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 840  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 850  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 860  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 870  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 880  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 890  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 900  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 910  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 920  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 930  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 940  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 950  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 960  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 970  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 980  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 990  |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1000 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1010 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1020 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1030 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1040 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1050 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1060 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1070 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1080 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1090 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1100 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1110 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1120 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1130 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1140 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1150 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1160 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1170 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1180 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1190 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1200 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1210 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1220 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1230 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1240 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1250 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1260 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1270 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1280 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1290 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1300 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1310 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1320 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1330 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1340 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1350 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1360 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1370 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1380 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1390 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1400 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1410 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1420 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1430 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1440 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1450 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1460 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1470 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1480 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1490 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1500 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1510 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1520 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1530 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1540 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1550 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1560 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1570 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1580 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1590 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1600 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1610 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1620 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1630 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1640 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1650 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1660 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1670 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1680 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1690 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1700 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1710 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1720 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1730 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1740 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1750 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1760 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1770 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1780 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1790 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1800 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1810 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1820 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1830 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1840 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1850 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1860 |
| CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG    | 1870 |

## (2) INFORMATION FOR SEQ ID NO:79:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 355 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

```

Met Ser Asn Ser Arg Arg Ser Leu Arg Trp Ser Trp Leu Leu Ser
      1           5           10          15
Val Leu Ala Ala Val Gly Leu Gly Leu Ala Thr Ala Pro Ala Glu Ala
      20          25          30
Ala Pro Pro Ala Leu Ser Glu Asp Arg Phe Ala Asp Phe Pro Ala Leu
      35          40          45
Pro Leu Asp Pro Ser Ala Met Val Ala Glu Val Ala Pro Glu Val Val
      50          55          60
Asn Ile Asn Thr Lys Leu Gly Tyr Asn Ala Val Gly Ala Gly Thr
      65          70          75          80
Gly Ile Val Ile Asp Pro Asn Gly Val Val Leu Thr Asn Asn His Val
      85          90          95
Ile Ala Gly Ala Thr Asp Ile Asn Ala Phe Ser Val Gly Ser Gly Gln
      100         105         110
Thr Tyr Gly Val Val Gly Tyr Asp Arg Thr Gln Asp Val Ala

```

| 119   | 120 | 121 |
|---|-----|-----|
| Val Leu Gln Leu Arg Gly Ala Gly Gly Leu Pro Ser Ala Ala Ile Gly |     |     |
| 122   | 123 | 124 |
| Gly Gly Val Ala Val Gly Glu Pro Val Val Ala Met Gly Asn Ser Gly |     |     |
| 125   | 126 | 127 |
| Gly Gln Gln Gly Thr Pro Arg Ala Val Pro Gly Arg Val Val Ala Leu |     |     |
| 128   | 129 | 130 |
| Gly Gln Thr Val Gln Ala Ser Asp Ser Leu Thr Gly Ala Gln Glu Thr |     |     |
| 131   | 132 | 133 |
| Leu Asn Gly Leu Ile Gln Phe Asp Ala Ala Ile Gln Pro Gly Asp Ser |     |     |
| 134   | 135 | 136 |
| Gly Gly Pro Val Val Asn Gly Leu Gly Gln Val Val Gly Met Asn Thr |     |     |
| 137   | 138 | 139 |
| Ala Ala Ser Asp Asn Phe Gln Leu Ser Gln Gly Gln Gly Phe Ala     |     |     |
| 140   | 141 | 142 |
| Ile Pro Ile Gly Gln Ala Met Ala Ile Ala Gly Gln Ile Arg Ser Gly |     |     |
| 143   | 144 | 145 |
| Gly Gly Ser Pro Thr Val His Ile Gly Pro Thr Ala Phe Leu Gly Leu |     |     |
| 146   | 147 | 148 |
| Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val Gln Arg Val Val |     |     |
| 149   | 150 | 151 |
| Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr Gly Asp Val Ile |     |     |
| 152   | 153 | 154 |
| Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr Ala Met Ala Asp |     |     |
| 155   | 156 | 157 |
| Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser Val Asn Tyr Gln |     |     |
| 158   | 159 | 160 |
| Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr Leu Ala Glu Gly |     |     |
| 161   | 162 | 163 |
| Pro Pro Ala   |     |     |
| 164   |     |     |

### Mtb8.4 (DPV)

(1) INFORMATION FOR SEQ ID NO:101:

(A) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 500 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

|  |     |
|--|-----|
| CGTGGCAATG TCGTTGACCG TCGGGGGCGCG CGTCGGCTCG CGCGATCCCG TGGAACCGCGTT | 50  |
| CATTAACACC ACCTGCAATT ACGGGCGAGT ATGGAGCTTCG CTCRAACCGAA CGCATCCCG   | 120 |
| CGCTTCGCGA CGTTTCGAG CCTTCACCGT GGCGCAGTCG TATTTGCCCA ATTTCCTCGC     | 180 |
| CGCACCGCCA CCTCAGCGCG CTGCGATGGC CGCCCAATTG CAGCTGTGCG CGGGGCGCGC    | 240 |
| ACAGTACATC CGCGTTGCG AGTCGGTTGC CGCTCTCTTGC AACAACTATT AAGCCCATGC    | 300 |
| CGCCCCATC CGCGGACCGG CGCTGGTGC CGCGCTTGG CGCGATGCC CGCGCTCTCA        | 360 |
| ACGGGCGCA TCGCGGAGC CGCGATGTC CGCCGCGCTA CGCGGATTC CGCGGCTCT         | 420 |
| CGCGGGCGCG CGTCCTCTGC CGAATGCTG CGGCGGGCGCG CATCCACTAG TTCTAGACCG    | 480 |
| CGCGGCCACCG CGCTGGAGCT   | 500 |

(2) INFORMATION FOR SEQ ID NO:102:

#### 4.2. SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 56 amino acids
  - (B) TYPE: amino acid
  - (C) STRANGENESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

### Мів11 (Тъ38-1)

(2) INFORMATION FOR SEQ ID NO:46:

#### 4.1. SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 327 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

```

CGGCACGAGA GACCCATGCC CCTACCTCGC CGCAGGAGTC AGGTAATTTC GAGCGGATCT    69
CGCGCGACCT GAAANCCCAAG ATCGACCGAGG TGGAACTCGAC CGCAAGGTGCG TTTCAGGGCC 130
ATGCGCCCGG CCCCGCGGGG AGCGCCCGCC AGGCACCGCTT GGTGCCTTC CAAGAACGAG 180
CCAATRAGCA GAAGCAGTAA CTGAACTCGA TCTCGACGAA TATTCGTCAG CGCGCGCTCG 340
AATACTCGAG CGCGCGACGAG GAGCAGCGGC AGGCGCTGTC CTCGCAALTG GCCTTCGTGAC 300
CCGCTAATAC GAAAGAAAC CGACCAA 327

```

(3) INFORMATION FOR SEQ ID NO:88:

### (ii) SOURCE CHARACTERISTICS:

- (A) LENGTH: 96 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Thr Asp Ala Ala Thr Leu Ala Gln Glu Ala Gly Asn Phe Glu Arg Ile  
 1                   5                   10                   15  
 Ser Gly Asp Leu Lys Thr Gln Ile Asp Gln Val Glu Ser Thr Ala Gly

|   |    |    |    |
|---|----|----|----|
| 28  | 28 | 30 |    |
| Ser Leu Gln Gly Gln Trp Arg Gly Ala Ala Gly Thr Ala Ala Gln Ala |    |    |    |
| 35  | 40 | 45 |    |
| Ala Val Val Arg Phe Gln Gln Ala Ala Asn Lys Gln Lys Gln Gln Leu |    |    |    |
| 50  | 55 | 60 |    |
| Asp Glu Ile Ser Thr Asn Ile Arg Gln Ala Gly Val Gln Tyr Ser Arg |    |    |    |
| 65  | 70 | 75 | 80 |
| Ala Asp Gln Glu Gln Gln Ala Leu Ser Ser Gln Met Gly Phe         |    |    |    |
| 85  | 90 | 95 |    |

**TbRa3**

## (2) INFORMATION FOR SEQ ID NO:15:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 942 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

|  |     |
|--|-----|
| GAATTCCGCA CGAGACGCTGA TGCACATCAT CGGAGACCAGC CCCACATCTT CGGAAACAGCC | 60  |
| CGCGCGCGAG CGCGTCGAGC CGCGCGCGGA TAGCGCTGAT GACATCGGGC TCGCTCGGGT    | 120 |
| CATTGACCGAG CACATGCCCG TGCACACGCC CGCGACAGATC AGCTAACCCA TCGAAGCTGA  | 180 |
| AGTGTTCGTT AAGATGAGNC CGGCGCGACC CGCGTACGAC CGCGCGCGGA CGAAGACCGA    | 240 |
| AAATCGCGCG TTTCGCGGTT GATTCGTCGG ATTTCGTCGTC TGCTCGCGCA CGCGTACCGA   | 300 |
| CGCGCGCGCA CGTCCCGCGT CTGCGCTATC CGCGCGTGC A TCGCGATTCG CGCGCGCGCC   | 360 |
| CGCGCGCGTA CGTCCCGCGT CGACCGAAC TCGCGATCC CGCGCGCGAC TCGCGATTCG      | 420 |
| CGCGCGCGAG CGCGCGCGTG CGCGCGTGC CGCGCGAAC CGCGCGTAGGA                | 480 |
| CGCGCGCGTA CGCGCGCGTG CTGACCGCGT CTGCGCTGC CGCGCGCGAC                | 540 |
| GG   | 542 |

## (2) INFORMATION FOR SEQ ID NO:77:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 66 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

|   |    |    |    |
|---|----|----|----|
| Val Ile Asp Ile Ile Gly Thr Ser Pro Thr Ser Tyr Gln Gln Ala Ala |    |    |    |
| 1   | 5  | 10 | 15 |
| Ala Glu Ala Val Gln Arg Ala Arg Asp Ser Val Asp Asp Ile Arg Val |    |    |    |
| 20  | 25 | 30 |    |
| Ala Arg Val Ile Glu Gln Asp Met Ala Val Asp Ser Ala Gly Lys Ile |    |    |    |
| 35  | 40 | 45 |    |
| Thr Tyr Arg Ile Lys Leu Glu Val Ser Phe Lys Met Arg Pro Ala Gln |    |    |    |
| 50  | 55 | 60 |    |
| Pro Arg   |    |    |    |
| 65  |    |    |    |

38kD

## (2) INFORMATION FOR SEQ ID NO:154:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1993 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

|   |      |
|---|------|
| TGTTCTTCCA CGGGCGCTTC GTCGAGGAAG GACCCACCGAA ACAGCTGTTC TCTCGCGGA     | 60   |
| AGCATCGGA AACCCCGCGA TACGTGCGG GACTGTGCGG GGACGTCAAG GACGCCAAGC       | 120  |
| GCGGATTC AAGGCGACAG AAAGGTATGC CCGAAAATTG CGTTTGCGTA CGCTTTCAGC       | 180  |
| CCTTGTGACC CCTCGCGCGC TGCTGTGAG AGCGCCGGGC TGTCGCTCGA AACCCACCGA      | 240  |
| CGTTGCGCT GAAACCGCGC CGCGCGCGC TACTGTGCGG ACTACCCCCG CGTCGCTCGC       | 300  |
| GGTGACCGTG CGCGACACCG CGTACCGCT CGTCTAACCG CGTCTCAACC TGTGGGGTCC      | 360  |
| GGCTTTACAC GAGACGATTC CGAACCTCAC GATCACCGCT CGACCGACCG GTTCTGGTCC     | 420  |
| CGCGATCGCG CGCGCGCGT CAACATTGCG CGCTCGACCG CCTATCTGTC                 | 480  |
| GGGAGCTAT ATCGCGCGGC ACAGCGCGT GATGACGCTC CGCGTACGCC TCTCCGGTCA       | 540  |
| GGAGCTCAAC TACGACCGTC CGCGACGTAG CGACCGCTTC AAGCTGAACG GAAACGTTT      | 600  |
| CGCGCGATG TACCGACCGA CGATCAAAC CTGGGACCGAC CGCGACGATG CGTCGCTCAA      | 660  |
| CCCGCGCTG AACCTGCGCG CGCGCGCTG ATTTCCCGTG CGCGCGCTCG AGCGCTCGCG       | 720  |
| TGACACCTTC TTGGTCAACCC AGTACCGTTC CAAGCGAGAT CGCGCGCTG CGGGCGAGTC     | 780  |
| CCCGCGCTTC CGCGACCGCG CGCGCTTCCC CGCGCGTGGCG CGTGCACCG CGTGCACCG      | 840  |
| CAACGGGGC ATCGTACCG CGTGCACCGA GACCGCGCT CGCGCGCGCT ATATCGGGAT        | 900  |
| CGCGCGCTTC GACCGACCGA GTCAACGGCG ACTCGCGCG CGCGCGCTAG CGAATAGCTC      | 960  |
| TGGCAATTTC TTGGTCCCG CGCGCGCGCG CGCGCGCTG CGCGCGCTG CGTGCACCG         | 1020 |
| GAACACCCCG CGCGACCGCG CGATTTGCGAT GATCGACCGCG CGCGCGCG CGCGCGACCA     | 1080 |
| GATCATGAC TACGACGTC CGATCGTCAA CGACCGCGAA AAGGACCGCG CGCGCGCGA        | 1140 |
| GAACCTTGCGA CGATTTGCG ACTCGCGCGAT CGACCGACCG AACACGGCGT CGTGCACCG     | 1200 |
| CGACGTTCAT TTGCGACCGCG CGTGCACCGCG CGTGCACCG CGTGCACCG CGTGCACCG      | 1260 |
| GAACGTTTCC AGCTACCGCTC GTGACCGACCG ACACCGACCG CGCGCGCTCG CGCGCGATGG   | 1320 |
| CGTGCCTTCC CGACGATGCT CGCGCGCTCG CGTGCACCG CGCGCGCTCG CGCGCGCGATC     | 1380 |
| CGCGCGCTTG CGTGCACCGCG CGCGCGCTG CGCGCGCTCG CGCGCGCTCG CGCGCGCTCG     | 1440 |
| CGTGCCTGCG CGTGCACCGCG CGCGCGCTG CGCGCGCTCG CGCGCGCTCG CGCGCGCTCG     | 1500 |
| ACCGAATGGA ATCCACCGCA CGACGACCGCG CGACCGCGCG CGTGCACCG CGCGCGCGCG     | 1560 |
| CGCGCGCGCG CTACTACCGCG CGGTTGCGCG TGTGCGTGG GACCGCGCG CGCGCGCGCG      | 1620 |
| TGCGCGCGAT CGTGCACCGCG CGCGCGCTCG TACGACCGCG CGTGCACCG CGCGCGCGCG     | 1680 |
| TGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG     | 1740 |
| CGTGCACCG CGTGCACCG CGTGCACCG CGTGCACCG CGTGCACCG CGTGCACCG CGTGCACCG | 1800 |
| CGTGCACCG CGTGCACCG CGTGCACCG CGTGCACCG CGTGCACCG CGTGCACCG CGTGCACCG | 1860 |
| CGGCGACCG CGACGCGCG CGTGCACCG CGTGCACCG CGTGCACCG CGTGCACCG CGTGCACCG | 1920 |
| TTATCGCCAC CGACCGCGAT CGACGACCGCG CGACGACCGCG CGTGCACCG CGTGCACCGCG   | 1980 |
| CGATCGCGAA TTC  | 1993 |

## (2) INFORMATION FOR SEQ ID NO:155:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 174 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

Met Lys Ile Arg Leu His Thr Leu Leu Ala Val Leu Thr Ala Ala Pro  
 1 5 10 15  
 Leu Leu Leu Ala Ala Ala Gly Cys Gly Ser Lys Pro Pro Ser Gly Ser  
 20 25 30 35  
 Pro Glu Thr Gly Ala Gly Thr Val Ala Thr Thr Pro Ala Ser  
 35 40 45  
 Ser Pro Val Thr Leu Ala Glu Thr Gly Ser Thr Leu Leu Tyr Pro Leu  
 50 55 60  
 Phe Asn Leu Trp Gly Pro Ala Phe His Glu Arg Tyr Pro Asn Val Thr  
 65 70 75 80  
 Ile Thr Ala Gln Gly Thr Gly Ser Gly Ala Gly Ile Ala Gln Ala Ala  
 85 90 95  
 Ala Gly Thr Val Asn Ile Gly Ala Ser Asp Ala Tyr Leu Ser Glu Gly  
 100 105 110  
 Asp Met Ala Ala His Lys Gly Leu Met Asn Ile Ala Leu Ala Ile Ser  
 115 120 125  
 Ala Gln Gln Val Asn Tyr Asn Leu Pro Gly Val Ser Glu His Leu Lys  
 130 135 140  
 Leu Asn Gly Lys Val Leu Ala Ala Met Tyr Gln Gly Thr Ile Lys Thr  
 145 150 155 160  
 Try Asp Asp Pro Gln Ile Ala Ala Leu Asn Pro Gly Val Asn Leu Pro  
 165 170 175  
 Gly Thr Ala Val Val Pro Leu His Arg Ser Asp Gly Ser Gly Asp Thr  
 180 185 190  
 Phe Leu Phe Thr Gln Tyr Leu Ser Lys Gln Asp Pro Glu Gly Trp Gly  
 195 200 205  
 Lys Ser Pro Gly Phe Gly Thr Thr Val Asp Phe Pro Ala Val Pro Gly  
 210 215 220  
 Ala Leu Gly Glu Asn Gly Asn Gly Met Val Thr Gly Cys Ala Glu  
 225 230 235 240  
 Thr Pro Gly Cys Val Ala Tyr Ile Gly Ile Ser Phe Leu Asp Gln Ala  
 245 250 255  
 Ser Gln Arg Gly Leu Gly glu Ala Gln Leu Gly Asn Ser Ser Gly Asn  
 260 265 270  
 Phe Leu Leu Pro Asp Ala Gln Ser Ile Gln Ala Ala Ala Gly Phe  
 275 280 285  
 Ala Ser Lys Thr Pro Ala Asn Gln Ala Ile Ser Met Ile Asp Gly Pro  
 290 295 300

Ala Pro Asp Gly Tyr Pro Ile Ile Asn Tyr Glu Tyr Ala Ile Val Asn  
 305 310 315 320  
 Asn Arg Gln Lys Asp Ala Ala Thr Ala Gln Thr Leu Gln Ala Phe Leu  
 325 330 335  
 His Trp Ala Ile Thr Asp Gly Asn Lys Ala Ser Phe Leu Asp Gln Val  
 340 345 350  
 His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu Ser Asp Ala Leu  
 355 360 365  
 Ile Ala Thr Ile Ser Ser  
 370

**DPEP**

## (2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 899 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

|             |             |             |              |              |              |     |
|-------------|-------------|-------------|--------------|--------------|--------------|-----|
| ATGCCATGACC | ATCACCCATCA | CATCGATCGAG | GTCGGACCCCCA | ACTTGACACCG  | TGGCAAGGGA   | 60  |
| CGATTTGGGG  | CACTGGCTAT  | CGCCGAAATC  | CGCGCGCCCA   | GCCTTGTTGAC  | GTTCGGGTC    | 130 |
| CCCCGGACGG  | CCCAACCGCGA | TCCGGAGCCA  | CGCGCGCGCG   | TACCCACAAAC  | GGCGCGCTCG   | 180 |
| CGCGCGTCCG  | CGCGTGCAGC  | CGCGACCGCA  | CGCGCGACAC   | CTTTTCCCCCCC | CTTAACCGACCG | 240 |
| CGCGCGCGCA  | ACAGCGCCAA  | TGGCGAGGCG  | CGCGATCCCA   | ACCGACCCACG  | TGGCGCGCGC   | 300 |
| CGACCGGACG  | CGACCGCGCC  | AAGTGTGATT  | GGCCCAAACG   | CAACCCAAACG  | TGTCCCGATC   | 360 |
| CGACGACCGG  | TTTGAGGATT  | CACTTGGCG   | CTCGCTCTG    | CTCGGGTTGA   | GTCGAGCGCC   | 420 |
| CGCCACCTCG  | ACTAACGGTTC | AGCACTCTTC  | AGCAAAACCA   | CGGGGGGACCC  | GCGATTTGCC   | 480 |
| CGGACGCGCG  | CGCCCGCTGGC | CAATGACACC  | CGTACGCTGC   | TGGCGCGCT    | AGACCAARAG   | 540 |
| CTTTTACGCCA | CGCCCGAAGC  | CAACGACTCC  | AGGGCGCGCG   | CGCGGTTGGG   | CTGGGACATG   | 600 |
| CGTGAGTTCT  | ATATGCCCTA  | CGCGGGGACC  | CGCATCAACG   | CTGGGTCGAC   | GGTGGACGCC   | 660 |
| CGCAACGGGG  | TGTCTGGAG   | CGCGTGTAT   | TACCAACTCA   | AGTTCAGGCA   | TGGGAGTAAG   | 720 |
| CGGAACGGCG  | CGCGTGTAC   | CGCGTGTAT   | CGCGTGTAC    | CGCGGACCGC   | ACGGGACGCC   | 780 |
| CGCGCCCCCTG | AGCGCTGGTT  | TGTGTATGG   | CTCGGGACCG   | CGAACAAACG   | GGTGGACAGG   | 840 |
| CGCGCGCGCGA | AGGGCGCTGC  | CGAATGATC   | CGCGCTTTGG   | TGGCGCGCGC   | GGCGGCGCG    | 900 |
| CGACCGGCTC  | CTCGAGAGCG  | CGCTCGGGCG  | CGCGCGCGCG   | CGGGGAACT    | CGCTCTAACG   | 960 |
| CGACGGACAC  | CGACGACCGA  | CGCGACCTTA  | CGCGCGCTGA   |              |              | 999 |

## (2) INFORMATION FOR SEQ ID NO:53:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 332 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Met His His His His His Met His Gln Val Asp Pro Asn Leu Thr  
 1 3 10 18  
 Arg Arg Lys Gly Arg Leu Ala Ala Leu Ala Ile Ala Ala Met Ala Ser  
 18 28 28 30  
 Ala Ser Leu Val Thr Val Ala Val Pro Ala Thr Ala Asn Ala Asp Pro  
 38 40 48  
 Glu Pro Ala Pro Pro Val Pro Thr Thr Ala Ala Ser Pro Pro Ser Thr  
 58 58 60  
 Ala Ala Ala Pro Pro Ala Pro Ala Thr Pro Val Ala Pro Pro Pro Pro  
 68 78 78 80  
 Ala Ala Ala Asn Thr Pro Asn Ala Gln Pro Gly Asp Pro Asn Ala Ala  
 88 90 90  
 Pro Pro Pro Ala Asp Pro Asn Ala Pro Pro Pro Pro Val Ile Ala Pro  
 108 108 110  
 Asn Ala Pro Gln Pro Val Arg Ile Asp Asn Pro Val Gly Gly Phe Ser  
 118 120 125  
 Phe Ala Leu Pro Ala Gly Trp Val Gln Ser Asp Ala Ala His Phe Asp  
 138 135 140  
 Tyr Gly Ser Ala Leu Leu Ser Lys Thr Thr Gly Asp Pro Pro Phe Pro  
 148 150 155 160  
 Gly Gln Pro Pro Pro Val Ala Asn Asp Thr Arg Ile Val Leu Gly Arg  
 168 170 175  
 Leu Asp Gln Lys Leu Tyr Ala Ser Ala Gln Ala Thr Asp Ser Lys Ala  
 188 188 190  
 Ala Ala Arg Leu Gly Ser Asp Met Gly Gln Phe Tyr Met Pro Tyr Pro  
 198 200 205  
 Gly Thr Arg Ile Asn Gln Gln Thr Val Ser Leu Asp Ala Asn Gly Val  
 218 218 220  
 Ser Gly Ser Ala Ser Tyr Tyr Glu Val Lys Phe Ser Asp Pro Ser Lys  
 228 230 235 240  
 Pro Asn Gly Gln Ile Trp Thr Gly Val Ile Gly Ser Pro Ala Ala Asn  
 245 250 255  
 Ala Pro Asp Ala Gly Pro Pro Gln Arg Trp Phe Val Val Trp Leu Gly  
 260 265 270  
 Thr Ala Asn Asn Pro Val Asp Lys Gly Ala Ala Lys Ala Leu Ala Gln  
 275 280 285  
 Ser Ile Arg Pro Leu Val Ala Pro Pro Pro Ala Pro Ala Pro Ala Pro  
 290 295 300  
 Ala Gln Pro Ala Pro Ala Pro Ala Gly Glu Val Ala Pro Thr  
 305 310 315 320  
 Pro Thr Thr Pro Thr Pro Gln Arg Thr Leu Pro Ala  
 325 330

**TbH4**

## (2) INFORMATION FOR SEQ ID NO:43:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 702 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

CCGCACGAGG ATCGGTACCC CGCGCGATCG CGAGCTCCCG ATTCGGCGCGG TTTCGGCGACC

60

|  |     |
|--|-----|
| CCAGGAAAGC CCTTACCAAGA TCCCCTGCCG GAACTGGCC GATCCCGTTGC CGATGCCCGC   | 120 |
| ATGAAACGGCC GGCATCAATT TGTGCGGGA ACCTTTCACT TTACCGACCA TAATGGCTAT    | 130 |
| AGCACTTAAGG AGCATGATCC GATATGACCC AGTGGCAGAC CCGGACCGTC GATCAGCAG    | 140 |
| AGATTTGAA CACGGCCAGC GAGGTGAGG CCCTGATGCC CGACCCACCC ACTGATGTCG      | 150 |
| CCATCACCCG CTGGCGACTC ACCCGGTTTA AAAAGCCCGC CCAACAGTTG GTTTGTCG      | 160 |
| CCGACAAACAT CGGGGATAAC CTGGCGGGCCG CTGGCGAAAGA CGGGCACGCT CTGGCGACCT | 170 |
| CGCTGGCCAA CGCCGCCAGG GNGTATGCCG AGGTTGATGA CGAGGCTCGC ACCGGCGCTCG   | 180 |
| ACAACGACCG CGAAGGAACT CTGGCGGCG AATCGCCCGG CGCCGTCGCA CGGACAGTT      | 190 |
| CGCCGAACT AACCGATACG CGAGGCTCG CGAAGGCGCG TGAACCCAAC TTCATGGATC      | 200 |
| TCAAAGGAGC CGCAGGAAAG CTCGAAACCG CGGACCAAGC CGCATCGTC CGGACTCG       | 210 |
| CGGATGCGTC GAACTGACCC TCGAAGGCCA CG                                  | 220 |

## (2) INFORMATION FOR SEQ ID NO:81:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 286 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

|   |     |     |     |
|---|-----|-----|-----|
| Gly Asp Ser Phe Trp Ala Ala Ala Asp Gin Met Ala Arg Gly Phe Val |     |     |     |
| 1   | 5   | 10  | 15  |
| Leu Gly Ala Thr Ala Gly Arg Thr Thr Leu Thr Gly Glu Gly Leu Glu |     |     |     |
| 20  | 25  | 30  |     |
| His Ala Asp Gly His Ser Leu Leu Asp Ala Thr Asn Pro Ala Val     |     |     |     |
| 35  | 40  | 45  |     |
| Val Ala Tyr Asp Pro Ala Phe Ala Tyr Glu Ile Gly Tyr Ile Xaa Glu |     |     |     |
| 50  | 55  | 60  |     |
| Ser Gly Leu Ala Arg Met Cys Gly Glu Asn Pro Glu Asn Ile Phe Phe |     |     |     |
| 65  | 70  | 75  | 80  |
| Tyr Ile Thr Val Tyr Asn Glu Pro Tyr Val Glu Pro Pro Glu Pro Glu |     |     |     |
| 85  | 90  | 95  |     |
| Asn Phe Asp Pro Glu Gly Val Leu Gly Ile Tyr Arg Tyr His Ala     |     |     |     |
| 100   | 105 | 110 |     |
| Ala Thr Glu Glu Arg Thr Asn Lys Xaa Glu Ile Leu Ala Ser Gly Val |     |     |     |
| 115   | 120 | 125 |     |
| Ala Met Pro Ala Ala Leu Arg Ala Ala Glu Met Leu Ala Ala Glu Trp |     |     |     |
| 130   | 135 | 140 |     |
| Asp Val Ala Ala Asp Val Trp Ser Val Thr Ser Trp Gly Glu Leu Asn |     |     |     |
| 145   | 150 | 155 | 160 |
| Arg Asp Gly Val Val Ile Glu Thr Glu Lys Leu Arg His Pro Asp Arg |     |     |     |
| 165   | 170 | 175 |     |
| Pro Ala Gly Val Pro Tyr Val Thr Arg Ala Leu Glu Asn Ala Arg Gly |     |     |     |
| 180   | 185 | 190 |     |
| Pro Val Ile Ala Val Ser Asp Tyr Met Arg Ala Val Pro Glu Glu Ile |     |     |     |
| 195   | 200 | 205 |     |
| Arg Pro Trp Val Pro Gly Thr Tyr Leu Thr Leu Gly Thr Asp Gly Phe |     |     |     |
| 210   | 215 | 220 |     |
| Gly Phe Ser Asp Thr Arg Pro Ala Gly Arg Arg Tyr Phe Asn Thr Asp |     |     |     |
| 225   | 230 | 235 | 240 |
| Ala Glu Ser Glu Val Gly Arg Gly Phe Gly Arg Gly Trp Pro Gly Arg |     |     |     |
| 245   | 250 | 255 |     |
| Arg Val Asn Ile Asp Pro Phe Gly Ala Gly Arg Gly Pro Pro Ala Glu |     |     |     |
| 260   | 265 | 270 |     |
| Leu Pro Gly Phe Asp Gly Gly Leu Arg Pro Xaa Lys                 |     |     |     |

|     |     |     |
|-----|-----|-----|
| 373 | 280 | 285 |
|-----|-----|-----|

## MTbRa12

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 447 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

|   |     |
|---|-----|
| CGGTATGAAAC ACGGCCGCGT CGGATAAATT CGGGCTGTCC CAGGGTCGGG AGGGATTGCC  | 60  |
| CGATTCGGATC GGGCAAGGGA TGGGATGCGC CGGGCAGATC CGATCGGGTG GGGGGTCACC  | 120 |
| CACCGTTCTT ATCGGGGCTA CGGGTTTCTT CGGGCTTGCGT GTTGTGCGACA ACAACGGCAA | 180 |
| CGGGCGACGA GTCCAACGGG TGTTCGGAG CGGGGGGGGG CGAAGTCGG GCGTGTGCGC     | 240 |
| CGGGGAGCTG ATCACGGGG TGACGGCGC TGGATCAAC TGGGCCACCG CGATGGCGGA      | 300 |
| CGGGCTTACG CGGCATCATC CGGGTACGT CGGGTGGGT AACGGGGAAA CGAAGTCGGG     | 360 |
| CGGGGACGGT ACAGGGGAGG TGACATTGGC CGGGGGACCC CGGGGCTGAT TTGTGCGCG    | 420 |
| ATACCGACGGG CGGGGGGGT AATGGAA                                       | 447 |

## (2) INFORMATION FOR SEQ ID NO:66:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 132 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

|   |     |
|---|-----|
| Thr Ala Ala Ser Asp Asn Phe Gln Ieu Ser Gln Gly Gly Gln Gly Thr |     |
| 1   | 5   |
| Ala Ile Pro Ile Gly Gln Ala Met Ala Ile Ala Gly Gln Ile Arg Ser |     |
| 20  | 25  |
| Gly Gly Gly Ser Pro Thr Val His Ile Gly Pro Thr Ala Phe Leu Gly |     |
| 35  | 40  |
| Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val Gln Arg Val |     |
| 50  | 55  |
| Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr Gly Asp Val |     |
| 65  | 70  |
| Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr Ala Met Ala |     |
| 85  | 90  |
| Asp Ala Leu Asn Gly His Pro Gly Asp Val Ile Ser Val Asn Trp     |     |
| 100   | 105 |
| Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr Leu Ala Glu |     |
| 115   | 120 |
| Gly Pro Pro Ala   |     |
| 130   |     |

(iii) INFORMATION FOR SEQ ID NO:240:

#### 4.1. **STRUCTURE CHARACTERISTICS:**

- (A) LENGTH: 319 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(b) MOLECULE TYPE: Genomic DNA

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:240:

|             |            |            |            |             |            |     |
|-------------|------------|------------|------------|-------------|------------|-----|
| ATGAAAGTTGA | ACTTTGGTCC | CCTGACTACT | GGGATCTCG  | CTTGTCGAGC  | GGGGCTTGTG | 60  |
| TTTCTCTGCT  | CGGTTGCCAG | CCGAGATCCA | CTTGACCGGC | ATCAGCCCCG  | CATGACGAAA | 130 |
| GGCTATTGCC  | CGGGTGGCCC | ATGGGGTTTT | GGGACTTCC  | CCGTGTTGGCA | CGGGCGAGAG | 180 |
| TACCGGACG   | GCTGGTTTTC | GGGACCTGG  | ATGCAAACGT | GGTTTACCGG  | GGCACAGTTT | 340 |
| TACTTGTATT  | GTGTCACCGG | GGGTGAGGCC | CTGGGGGGCC | GGGGGACACC  | GGGTGGTTGC | 390 |
| CGTGGCGAA   | TTCTGCTCGA | GGAGCCCAAC | CTCTCTTGA  |             |            | 339 |

(2) INFORMATION FOR CASE ID NO.: 241:

### **4.3 SENTENCE CHARACTERISTICS:**

- (A) LENGTH: 112 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

### (iii) MOLECULE TYPE: protein

(x4) sequence description: seq ID NO:241<

ESAT-6

(2) INFORMATION FOR SEQ ID NO:103:

#### (4) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 154 base pairs  
 (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

|  |     |
|--|-----|
| ATGACAGAGGC ACCAGTGGAA TTTCCCGGT ATCCAGGCG CGCCGAGGCC AATCCAGGGA | 60  |
| AATGTCACGT CCATTCAATC CCTCTCTTAC GGGGGAAAGC AGTCCCTGAC CAGCTCGA  | 120 |
| CCGGGCTTCCG CGCTTACGGG TTCCGAGCC TACG                            | 154 |

## (xii) INFORMATION FOR SEQ ID NO:104:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 51 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

|   |    |    |    |
|---|----|----|----|
| Met Thr Glu Ala Glu Trp Asn Phe Ala Gly Ile Glu Ala Ala Ala Ser |    |    |    |
| 1   | 8  | 10 | 15 |
| Ala Ile Glu Gly Asn Val Thr Ser Ile His Ser Leu Leu Asp Glu Gly |    |    |    |
| 20  | 28 | 30 |    |
| Lys Glu Ser Leu Thr Lys Leu Ala Ala Ala Trp Gly Gly Ser Gly Ser |    |    |    |
| 35  | 40 | 45 |    |
| Glu Ala Tyr   |    |    |    |
| 50  |    |    |    |

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/08008**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7): A61K 36/005, 36/00, 36/00; C07K 1/00.  
 US CL : 435/248.1, 224.1, 185.1, 192.1; 550/550.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/248.1, 224.1, 185.1, 192.1; 550/550.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.       |
|-----------|--|-----------------------------|
| X, P      | WO 99/51748 A2 (CORIXA CORPORATION) 14 October 1999,<br>see entire document.   | 18-28 and 72-79             |
| Y, P      | HENDRICKSON et al. Mass spectrometric identification of Mtb81, a novel serological marker for tuberculosis. J. Clin. Microbiol. June 2000, Vol. 38, No. 6, pages 2354-2361, see entire document. | 1-3, 18-28, 56-58 and 72-79 |
| Y, P      | BRANDT et al. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. February 2000, Vol. 68, No. 2, pages 791-795, see entire document.                                   | 18-28 and 72-79             |

|                                     |  |                          |  |
|-------------------------------------|--|--------------------------|--|
| <input checked="" type="checkbox"/> | Further documents are listed in the continuation of Box C.   | <input type="checkbox"/> | See patent family names.   |
| *P                                  | Special categories of cited documents:   |                          |  |
| *A*                                 | Document defining the general state of the art which is not considered to be of particular relevance   | *T*                      | Later document published after the international filing date or priority date and not in conflict with the application but used to understand the principle or theory underlying the invention   |
| *B*                                 | earlier document published on or after the international filing date   | *Z*                      | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the difference is taken alone   |
| *C*                                 | document which may prove useful as priority claimed) or which is cited to establish the publication date of another citation or other special reasons (as specified) | *Y*                      | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the difference is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *D*                                 | document referring to an oral disclosure, use, exhibition or other means   | *W*                      | document number of the same patent family  |
| *E*                                 | document published prior to the international filing date but later than the priority date claimed   |                          |  |

|   |  |
|---|--|
| Date of the actual completion of the international search<br><br>on DECEMBER 2000   | Date of mailing of the international search report<br><br><b>06 FEB 2001</b>                       |
| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231<br>Facsimile No. (703) 308-9330 | Authorized officer<br><br><i>Steve Budgett</i><br>S. BUDGETT, S.D.<br>Telephone No. (703) 308-9196 |

## INTERNATIONAL SEARCH REPORT

|   |
|---|
| International application No.<br>PCT/US99/36098 |
|---|

## C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|-----------|---|-----------------------|
| Y, P      | ALDERSON et al. Expression cloning of an immunodominant family of <i>Mycobacterium tuberculosis</i> antigens using human CD4+ T cells. <i>J. Exp. Med.</i> 07 February 2000, Vol. 191, No. 3, pages 551-559, see entire document.   | 18-28 and 72-79       |
| Y         | COLER et al. Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of <i>Mycobacterium tuberculosis</i> . <i>J. Immunol.</i> 01 September 1998, Vol. 161, No. 5, pages 2356-2364, see entire document.   | 18-28 and 72-79       |
| Y         | ZIMMERMAN et al. Immunization with peptide heteroconjugates primes a T helper cell type 1-associated antibody (IgG2a) response that recognizes the native epitope on the 38-kDa protein of <i>Mycobacterium tuberculosis</i> . <i>Vaccine Res.</i> 1996, Vol. 6, No. 2, pages 103-113, see entire document. | 18-28 and 72-79       |
| Y         | LIAO et al. Immunological and functional characterization of proteins of the <i>Mycobacterium tuberculosis</i> antigen 85 complex using synthetic peptides. <i>J. Gen. Microbiol.</i> 1993, Vol. 139, pages 1543-1549, see entire document.   | 18-28 and 72-79       |
| Y         | VORDERMEIER et al. Synthetic delivery system for tuberculosis vaccine: immunological evaluation of the <i>M. tuberculosis</i> 38 kDa protein entrapped in biodegradable PLG microparticles. <i>Vaccine</i> 1995, Vol. 13, No. 16, pages 1576-1582, see entire document.                                     | 18-28 and 72-79       |
| Y         | LOWRIE et al. Progress towards a new tuberculosis vaccine. <i>BioDrugs</i> September 1998, Vol. 10, No. 3, pages 201-213, see entire document.  | 18-28 and 72-79       |

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/06003

### Box I. Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  **Claims Nos.:**  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  **Claims Nos.:**  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  **Claims Nos.:**  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 8.4(a).

### Box II. Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-3, 18-28, 36-38 and 72-78

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/08888

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used)

DIALOG, MEDLINE, EMBASE, WEST, BIOSIS, PASCAL.

Mycobacteri, Mtb, MTb<sub>1</sub>, TbRas, esAT3, TbcA-1, MTb<sub>11</sub>, FL TbN4, HTCC#1, Mtb<sub>65</sub>, TbHb, MTCC#8, MTb<sub>87</sub>, DPEP, DPPD, TbRas<sub>2</sub>, TbRas<sub>3</sub>, MTbss, Mtbss, Radix, Mtbss, FL TbRas<sub>2</sub>, MtbssA, DPV, MTbss<sub>4</sub>, MSL, MTbss, MTI, MTbssA, MTI-A, RSAT-4, alpha-crystallin, 88 complex.

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-4 and 50-58, drawn to a pharmaceutical composition comprising a mycobacterial MTb<sub>1</sub> antigen and an Mtb antigen and a method of eliciting an immune response by administering the same.

Group II, claims 4-6, 50-51, 107 and 108, drawn to a pharmaceutical composition comprising a mycobacterial TbRas, a 88 kD antigen, a TbcA-1 antigen and a FL TbHb antigen, a fusion protein comprising the same and a method of eliciting an immune response by administering the composition.

Group III, claims 7-14, 50-58 and 109-118, drawn to a pharmaceutical composition comprising a mycobacterial HTCC#1 and a TbHb antigen, a fusion protein comprising the same and a method of eliciting an immune response by administering the composition.

Group IV, claims 15-17, 50-71, 114 and 115, drawn to a pharmaceutical composition comprising a mycobacterial TbRas<sub>2</sub> antigen and an HTCC#1 antigen, a fusion protein comprising the same and a method of eliciting an immune response by administering the composition.

Group V, claims 50-58 and 50-58, an expression cassette comprising nucleic acids encoding mycobacterial MTb<sub>1</sub> and Mtb antigens and a method of eliciting an immune response by administering the same.

Group VI, claims 50-58 and 50-57, drawn to an expression cassette comprising nucleic acids encoding mycobacterial TbRas, a 88 kD antigen, a TbcA-1 antigen and a FL TbHb antigen and a method of eliciting an immune response by administering the same.

Group VII, claims 57-58 and 58-58, drawn to an expression cassette comprising nucleic acids encoding mycobacterial HTCC#1 and TbHb antigen and a method of eliciting an immune response by administering the same.

Group VIII, claims 47-50 and 50-58, drawn to an expression cassette comprising nucleic acids encoding mycobacterial TbRas<sub>2</sub> and HTCC#1 antigens and a method of eliciting an immune response by administering the same.

Claims 10-58 and 70-70 are considered linking claims and would be joined with one of inventions I, II, III and IV, if elected.

Claims 51-58 and 100-100 are considered linking claims and would be joined with one of inventions V, VI, VII and VIII, if elected.

The inventions listed as Groups I through VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.8, they lack the same or corresponding special technical features for the following reasons:

Inventions I through IV are drawn to compositions comprising distinct mycobacterial antigens and methods of using the same. Inventions V through VIII are drawn to four different expression cassettes and methods of using the same. Clearly, the special technical features of inventions I through VIII is not a unifying feature and there is no single general inventive concept underlying the plurality of claimed inventions of the present application in the sense of PCT Rule 13.1. Consequently, the application lacks unity of invention.